Poster Presentations

POSTER PRESENTATIONS SESSION I
SET-UP:	Sunday, 25 October, 11:30 – 12:00
POSTER DISPLAY HOURS:	Sunday, 25 October, 12:00 – 19:30
POSTER AUTHOR DISCUSSION HOUR:	Sunday, 25 October, 17:30 – 18:30
DISMANTLE:	Sunday, 25 October, 19:30 – 20:00

HEALTH CARE USE & POLICY STUDIESConsumer Role in Health Care

PHP1	THE COMMERCIALIZATION OF HEALTH CARE ALLOCATION: CONSUMERS' TOTAL AND DISTRIBUTIONAL HEALTH OUTCOME PERCEPTIONS AND ATTITUDE TOWARDS FLEXIBLE CARE ACCESS PRICING STRATEGIES BY HOSPITALS
	Benning T, Dellaert BGC Erasmus University Rotterdam, Rotterdam, The Netherlands

PHP2	PREDICTING PERSISTENT FREQUENT USE OF THE PRIMARY HEALTH CARE SERVICES IN A FINNISH SETTING: A BAYESIAN APPROACH
	Koskela T¹, Ryynänen OP², Soini EJ³ ¹Department of General Practice, University of Tampere, Tampere, Finland, ²General Practice Unit, Kuopio University Hospital, and Department of General Practice, University of Kuopio, Kuopio, Finland, ³ESiOR Oy, Department of Health Policy and Management, and Department of Social Pharmacy, University of Kuopio, Kuopio, Finland

PHP3	EFFECTS OF THE IMPLEMENTATION OF AN ANNUAL CO-PAYMENT LIMIT FOR PRESCRIPTION DRUGS IN AUSTRIA
	Ortner T, Heiderer B, Ganjeizadeh-Rouhani A Main Association of Austrian Social Security Institutions, Vienna, Vienna, Austria

PHP4	USE OF FREE MEDICINE SAMPLES, DOCTOR PATIENT COMMUNICATION AND COST-RELATED NON-ADHERENCE AMONG OLDER ADULTS
	Donohue JM¹, Huskamp H², Zhang Y¹, Safran D³, Gellad WF⁴ ¹University of Pittsburgh, Pittsburgh, PA, USA, ²Harvard Medical School, Boston, MA, USA, ³Blue Cross Blue Shield of Massachusetts, boston, MA, USA, ⁴RAND, Pittsburgh, PA, USA

HEALTH CARE USE & POLICY STUDIESDiagnosis Related Group

PHP5	RISK OF DEATH AND HOSPITAL LENGTH OF STAY ASSOCIATED WITH CLINICAL EVENTS POTENTIALLY CAUSED BY NEUROMUSCULAR BLOCKADE REVERSAL AGENTS
	Félix J¹, Calado F², Rabiais S², Vilela H³ ¹Exigo Consultores, Alhos Vedros, Lisbon, Portugal, ²Exigo Consultores, Alhos Vedros, Portugal, ³Hospital Fernando Fonseca, Amadora, Portugal

PHP6	ACUT CARE HOSPITAL BED OCCUPANCY RATE IN HUNGARY BETWEEN 2000 AND 2008
	Gresz M¹, Varga S², Kriszbacher I², Boncz I² ¹National Health Insurance Fund Administration (OEP), Budapest, Hungary, ²University of Pécs, Pécs, Hungary

PHP7	BED OCCUPANCY RATE OF HUNGARIAN INTENSIVE CARE UNITS
	Varga S¹, Gresz M², Ágoston I¹, Vas G¹, Sebestyén A³, Betlehem J¹, Kriszbacher I¹, Nagy Z⁴, Boncz I¹ ¹University of Pécs, Pécs, Hungary, ²National Health Insurance Fund Administration (OEP), Budapest, Hungary, ³National Health Insurance Fund Administration, Pécs, Hungary, ⁴Health Insurance Supervisory Authority, Budapest, Hungary

HEALTH CARE USE & POLICY STUDIESDisease Management
PHP8	SURVEY ON THE MANAGEMENT OF ORAL ANTICOAGULATION THERAPY (OAT) IN ITALY
	Iannazzo S¹, Zaniolo O¹, Botrugno P² ¹AdRes HE&OR, Torino, Italy, ²Roche Diagnostics S.p.A., Monza (MI), Italy

HEALTH CARE USE & POLICY STUDIESDrug/Device/Diagnostic Use & Policy
PHP9	HELSPOR'S ASSESSMENT OF THE PHARMACEUTICAL POLICY REFORMS IN GREECE: COST-CONTAINMENT AND ECONOMIC EVALUATION CRITERIA
	Kousoulakou H¹, Papanicolaou S², Geitona M³ ¹Foundation for Economic & Industrial Research, Athens, Greece, ²PRMA Consulting Ltd, Hampshire, UK, ³University of Thessaly, volos, Greece

PHP10	QUALITY ASSURANCE OF FOURTH HURDLE IN HUNGARY – A METHODOLOGICAL APPROACH
	Kalo Z¹, Pekli M², Inotai A³ ¹Eotvos Lorand University, Budapest, Hungary, ²National Institute for Strategic Health Research, Budapest, Hungary, ³Semmelweis University, Budapest, Hungary

PHP11	DOES PHARMACEUTICAL CONSUMPTION IMPROVE HEALTH CARE STATUS?
	Grandfils N¹, Hauser S², Amalric F², Le Pen C³ ¹IMS, PUTEAUX, France, ²IMS Health, PUTEAUX, France, ³Paris Dauphine University, PARIS, France

PHP12	SHORTAGES IN THE AMERICAN MEDICAL DRUG MARKET
	Stino M, McGhan WF University of the Sciences in Philadelphia, Philadelphia, PA, USA

PHP13	CALCULATION OF DELAY OF DECISION-MAKING ON PHARMACEUTICAL REIMBURSEMENT IN SIMPLIFIED PROCEDURE IN HUNGARY
	Nagy Z¹, Molnár MP², Sebestyén A³, Kriszbacher I⁴, Ágoston I⁴, Vas G⁴, Varga S⁵, Boncz I⁴ ¹Health Insurance Supervisory Authority, Budapest, Hungary, ²National Health Insurance Fund Administration (OEP), Budapest, Budapest, Hungary, ³National Health Insurance Fund Administration, Pécs, Hungary, ⁴University of Pécs, Pécs, Hungary, ⁵University of Pécs, Pecs, Hungary

PHP14	A POLICY ANALYSIS OF THE PORTUGUESE GENERIC MEDICINES MARKET
	Simoens S Katholieke Universiteit Leuven, Leuven, Belgium

PHP15	BIOSIMILARS: HGH TO TNFS, HOW WILL PAYERS RESPOND?
	Long M¹, Trout J², Akpinar P¹ ¹PriceSpective, London, UK, ²PriceSpective, Blue Bell, PA, USA

PHP16	PARALLEL TRADE OF PHARMACEUTICALS IN POLAND
	Baran-Lewandowska I, Hermanowski T Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland

PHP17	CAN ELECTRONIC NOTIFICATIONS ABOUT SUBSTITUTES CHANGE PHYSICIANS' DRUG PRESCRIPTION HABITS? DEFINITELY YES!
	Zuker A¹, Heart T², Pliskin N², Pliskin JS² ¹Roshtov Software Inc., Omer, Israel, ²Ben-Gurion University of the Negev, Beer Sheva, Israel

PHP18	COMPARATIVE ANALYSIS OF THE IMPACT OF POSITIVE DRUG LIST SYSTEM BETWEEN NEW DRUGS VS INCREMENTALLY MODIFIED DRUGS IN SOUTH KOREA
	Ha DM¹, Lee EK² ¹Sungkyunkwan University, Suwon, Gyeonggi-do, South Korea, ²Sook Myung Women's University, Seoul, South Korea

PHP19	APPLYING "VALUE BASED" PRICING TO REGENERATIVE MEDICINE BASED PHARMACEUTICALS
	Watch J, Mackenzie AJ, Kefalas P, Whitcher C PriceSpective, London, UK

PHP20	COST-EFFECTIVE PHARMACEUTICAL CARE IN THE NETHERLANDS? A REVIEW OF THE PHARMACOECONOMICS AND ITS ROLE IN THE ASSESSMENT AND REIMBURSEMENT OF NEW DRUGS
	Hoomans T¹, Roer NVD², Severens JL³, Delwel G⁴ ¹Maastricht University, Maastricht, The Netherlands, ²CVZ Health Care Insurance Board, Diemen, The Netherlands, ³University Hospital Maastricht, Maastricht, The Netherlands, ⁴CVZ Healthcare Insurance Board, Diemen, The Netherlands

PHP21	THE ROLE OF MONETARY AND NON-MONETARY INCENTIVES ON THE CHOICE OF PRACTICE ESTABLISHMENT: A STATED PREFERENCE STUDY OF YOUNG PHYSICIANS IN GERMANY
	Günther OH¹, Kürstein B², Riedel-Heller SG³, Koenig HH² ¹i3 Innovus Berlin, Berlin, Germany, ²University of Leipzig, Leipzig, Germany, ³University of Leipzig, Leipzig, Saxony, Germany

PHP22	TOO MANY AGENCIES FOR DRUG EVALUATION IN SPAIN?
	Collar JM Grunenthal Pharma, S.A., Madrid, Spain

PHP23	GENERAL PRACTITIONERS' PRESCRIPTIONS INDICATORS TRENDS, A TIME-SERIES REVIEW DURING 1998–2003 IN IRAN
	Soleymani F Tehran University of Medical Science (TUMS), Tehran,Iran, Iran

PHP24	ANTIPSYCHOTICS CONSUMPTION IN THE REPUBLIC OF CROATIA IN 2005, 2006 AND 2007
	Draganic P¹, Zezelic S², Macolic-Sarinic V³, Tomic S³ ¹Agency for Medicinal Products and Medicinal Devices, Zagreb, Croatia, ²Agency for Medicinal Pproducts and Medical Devices, Zagreb, Croatia, ³Agency for Medicinal Products and Medical Devices, Zagreb, Croatia

PHP25	IMPACT OF REDUCED COPAYMENTS ON MEDICATION ADHERENCE: DX-RX PAIRING^TM PROGRAM OUTCOMES
	Kim YA¹, Smithline N², Serxner S³, Yokoyama G¹ ¹University of California, San Francisco, San Francisco, CA, USA, ²Mercer, San Francisco, CA, USA, ³Mercer, Los Angeles, CA, USA

PHP26	IMPOVERISHING MEDICINES: A CROSS-COUNTRY COMPARISON OF THE AFFORDABILITY OF MEDICINES
	Niëns LM Erasmus University Rotterdam, Rotterdam, The Netherlands

PHP27	ASSESSMENT OF THE INTERNATIONAL NONPROPRIETARY NAMES (INN) PRESCRIBING PILOT PROJECT IN SOUTH KOREA
	Kim JY, Lee EK Sook Myung Women's University, Seoul, South Korea

PHP28	PHARMACEUTICAL CARE IN THE EYES OF THE PATIENT
	Pilat-Nalecz K¹, Hermanowski T² ¹Medical University of Warsaw, Warsaw, Poland, ²Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland

HEALTH CARE USE & POLICY STUDIESEquity and Access
PHP29	UN POUR TOUT, TOUT POUR UN? AN EMPIRICAL ANALYSIS OF PHARMACEUTICAL COVERAGE DECISIONS IN THREE COUNTRIES
	Harris A Monash University, Clayton, VIC, Australia

PHP30	PRIMARY CARE AND AVOIDABLE HOSPITALIZATIONS: A COMPARATIVE ANALYSIS BETWEEN FRANCE AND THE UK
	Mansour E¹, Le Pen C², Nestrigue C³, Amalric F¹ ¹IMS Health, Puteaux, Ile de France, France, ²Dauphine University, Paris, France, ³IMS Health, Puteaux, France

PHP31	A POLICY FRAMEWORK FOR FUNDING DRUGS FOR RARE DISEASES
	Clarke J¹, Bell C², Coyle D³, Stevenson H⁴, Evans G⁵, Martin J⁶, Sabharwal M⁴, Gadhok A⁴, Winquist E⁶ ¹Hospital for Sick Children, Toronto, Ontario, Canada, ²Department of Medicine, St. Michael's Hospital, Toronto, ON, Canada, ³University of Ottawa, Ottawa, ON, Canada, ⁴Ontario Public Drug Programs, North York, ON, Canada, ⁵Queen's University, Kingston, ON, Canada, ⁶University of Western Ontario, London, ON, Canada

PHP32	THE USEFULNESS AND CHALLENGES OF PATIENT ACCESS (RISK SHARING) SCHEMES IN THE UK
	Lucas F¹, Easley C¹, Jackson G² ¹Pope Woodhead and Associates, St Ives, UK, ²Cambridge University, Cambridge,, UK

PHP33	PERCEPTIONS OF THE SAUDI STUDENTS ATTENDING AMERICAN UNIVERSITIES TOWARDS THE NEW SAUDI MANDATORY COOPERATIVE HEALTH INSURANCE PROGRAM (MCHIP) IMPLEMENTED IN SAUDI ARABIA
	Al-Shawairkh AS¹, Bradford JB² ¹Security Forces Hospital Program, Riyadh, Saudi Arabia, ²Virginia Commonwealth University, Ricmond, VA, USA

PHP34	USING DISCRETE CHOICE EXPERIMENT MODELLING TO ASSESS PREFERENCES FOR HEALTH SYSTEM CHARACTERISTICS IN THE UNITED KINGDOWM AND AUSTRALIA
	Taylor M¹, Saxby R¹, Scuffham PA², Whitty JA³ ¹University of York, York, UK, ²Griffith University, Meadowbrook, QLD, Australia, ³Griffith University, Brisbane, Queensland, Australia

PHP35	COMPARATIVE ASSESSMENT OF POSITIVE REIMBURSEMENT LISTS AND HTA EFFECTIVENESS IN ADRIATIC REGION
	Gavrankapetanovic I¹, Vitezic D², Gavrankapetanovic F¹, Francetic I³, Bolanca S⁴ ¹Clinical Center University of Sarajevo, Sarajevo, Bosnia, ²Pfizer Croatia, Zagreb, Croatia, ³University Hospital Centre Rijeka, Rijeka, Croatia, ⁴University Hospital Center Zagreb, Zagreb, Croatia

HEALTH CARE USE & POLICY STUDIESEquity and Access
PHP29	UN POUR TOUT, TOUT POUR UN? AN EMPIRICAL ANALYSIS OF PHARMACEUTICAL COVERAGE DECISIONS IN THREE COUNTRIES
	Harris A Monash University, Clayton, VIC, Australia

PHP30	PRIMARY CARE AND AVOIDABLE HOSPITALIZATIONS: A COMPARATIVE ANALYSIS BETWEEN FRANCE AND THE UK
	Mansour E¹, Le Pen C², Nestrigue C³, Amalric F¹ ¹IMS Health, Puteaux, Ile de France, France, ²Dauphine University, Paris, France, ³IMS Health, Puteaux, France

PHP31	A POLICY FRAMEWORK FOR FUNDING DRUGS FOR RARE DISEASES
	Clarke J¹, Bell C², Coyle D³, Stevenson H⁴, Evans G⁵, Martin J⁶, Sabharwal M⁴, Gadhok A⁴, Winquist E⁶ ¹Hospital for Sick Children, Toronto, Ontario, Canada, ²Department of Medicine, St. Michael's Hospital, Toronto, ON, Canada, ³University of Ottawa, Ottawa, ON, Canada, ⁴Ontario Public Drug Programs, North York, ON, Canada, ⁵Queen's University, Kingston, ON, Canada, ⁶University of Western Ontario, London, ON, Canada

PHP32	THE USEFULNESS AND CHALLENGES OF PATIENT ACCESS (RISK SHARING) SCHEMES IN THE UK
	Lucas F¹, Easley C¹, Jackson G² ¹Pope Woodhead and Associates, St Ives, UK, ²Cambridge University, Cambridge,, UK

PHP33	PERCEPTIONS OF THE SAUDI STUDENTS ATTENDING AMERICAN UNIVERSITIES TOWARDS THE NEW SAUDI MANDATORY COOPERATIVE HEALTH INSURANCE PROGRAM (MCHIP) IMPLEMENTED IN SAUDI ARABIA
	Al-Shawairkh AS¹, Bradford JB² ¹Security Forces Hospital Program, Riyadh, Saudi Arabia, ²Virginia Commonwealth University, Ricmond, VA, USA

PHP34	USING DISCRETE CHOICE EXPERIMENT MODELLING TO ASSESS PREFERENCES FOR HEALTH SYSTEM CHARACTERISTICS IN THE UNITED KINGDOWM AND AUSTRALIA
	Taylor M¹, Saxby R¹, Scuffham PA², Whitty JA³ ¹University of York, York, UK, ²Griffith University, Meadowbrook, QLD, Australia, ³Griffith University, Brisbane, Queensland, Australia

PHP35	COMPARATIVE ASSESSMENT OF POSITIVE REIMBURSEMENT LISTS AND HTA EFFECTIVENESS IN ADRIATIC REGION
	Gavrankapetanovic I¹, Bolanca S², Vitezic D³, Gavrankapetanovic F¹, Francetic I⁴ ¹Clinical Center University of Sarajevo, Sarajevo, Bosnia, ²Pfizer Croatia, Zagreb, Croatia, ³University Hospital Centre Rijeka, Rijeka, Croatia, ⁴University Hospital Center Zagreb, Zagreb, Croatia

HEALTH CARE USE & POLICY STUDIESFormulary Development
PHP36	HEALTH ECONOMICS DATA: USE AND PERCEIVED VALUE IN U.S. PAYERS' FORMULARY DECISIONS
	Mullins CD¹, Ratner J², Ball D³ ¹University of Maryland, Baltimore, MD, USA, ²Westat, Rockville, MD, USA, ³Eli Lilly and Company, Indianapolis, IN, USA

HEALTH CARE USE & POLICY STUDIESHealth Care Costs & Management
PHP37	SOCIAL HEALTH INSURANCE, PREVENTIVE CARE AND HEALTH CARE EXPENDITURE
	Chen Q¹, Li J², Li L¹ ¹Peking University, Beijing, China, ²Peking University, Beijing, Beijing, China

PHP38	HOSPITALIZATION COST OF PATIENTS ADMITTED TO THE TEACHING UNIVERSITY HOSPITAL OF LARISSA (TUHL) IN THE REGION OF THESSALY
	Androutsou L¹, Theodoratou D², Geitona M² ¹University of Thessaly, Athens, Greece, ²University of Thessaly, Volos, Greece

PHP39	COST MEASURE IN PRIMARY CARE: RETROSPECTIVE BEHAVIOUR OF ACG CASE-MIX SYSTEM AT A SPANISH INTERREGIONAL LEVEL
	Sicras-Mainar A¹, Navarro-Artieda R², Velasco-Velasco S¹, Escribano-Herranz E³, Prados S⁴, Estelrich J⁵ ¹Badalona Serveis Assistencials SA, Barcelona, Spain, ²Hospital Germans Trias y Pujol, Badalona, Barcelona, Spain, ³Badalona Serveis Assistencials SA, Badalona, Barcelona, Spain, ⁴Instituto aragonés de ciencias de la Salud, Barcelona, Spain, ⁵Badalona Servicios Asistenciales, Barcelona, Spain

PHP40	THE CONCENTRATION OF PHARMACEUTICAL MARKET IN SOME MEDICINE GROUPS IN FINLAND
	Heikkonen TT¹, Tamminen N² ¹University of Turku, Turku, Finland, ²Pharma Industry Finland, Helsinki, Uusimaa, Finland

PHP41	LUMP SUM REIMBURSEMENT OF PHARMACEUTICALS IN HOSPITALS IN BELGIUM: ASSESSING THE ADVERSE EFFECTS
	Arickx F, Soete E, VanHaeren E, Bormans V RIZIV-INAMI National Health Insurance Agency, Brussels, Belgium

PHP42	PHARMACEUTICAL EXPENDITURE AND POTENTIAL AVENUES FOR COST CONTAINMENT IN IRELAND
	Heaney RM¹, Judge G¹, Fortescue-Webb D¹, Coughlan JJ¹, Barry M² ¹Trinity College Dublin, Dublin 8, Dublin, Ireland, ²National Centre for Pharmacoeconomics, Dublin, Ireland

PHP43	INTERNATIONAL PAYER RESARCH: COMPARING AND CONTRASTING PAYER ROLES AND RESEARCH METHODS IN CANADA, SPAIN, AND THE UK
	de Cambra S¹, Mladsi D², Neale S³ ¹RTI Health Solutions, Barcelona, Spain, ²RTI Health Solutions, Research Triangle Park, NC, USA, ³RTI-Health Solutions, Ottawa, Ontario, Canada

PHP44	WITHDRAWN

PHP45	THE RAPID ADOPTION OF HEALTH TECHNOLOGY ASSESSMENT IN MIDDLE INCOME COUNTRIES - WHAT INFLULENCE DOES IT HAVE ON PHARMACEUTICAL REIMBURSEMENT. RESULTS FROM A SURVEY OF HEALTHCARE DECISION-MAKERS IN 11 COUNTRIES
	White J Novo Nordisk A/S, Zurich, Switzerland

PHP46	WTP FOR A QALY: THE INDIVIDUAL PERSPECTIVE
	Bobinac A Erasmus University, Rotterdam, The Netherlands

PHP47	EARLY ASSESSMENT OF HIGHLY INNOVATIVE MEDICAL TECHNOLOGY: CLINICAL AND ECONOMICAL GAINS OF POINT-OF-CARE APPLICATIONS FOR MEASURING POTASSIUM CONCENTRATIONS
	Wetering G, Hummel JM, Montfort A, IJzerman MJ University of Twente, Enschede, The Netherlands

PHP48	A NEW TEST OF THE CARERQOL INSTRUMENT: MEASURING ‘CARE-RELATED QUALITY OF LIFE' OF INFORMAL CAREGIVERS FOR USE IN ECONOMIC EVALUATIONS
	Hoefman RJ, Exel NJA, Redekop WK, Brouwer WBF ErasmusMC, Rotterdam, The Netherlands

PHP49	PALLIATIVE CARE AND ITS REIMBURSEMENT FOR OUTPATIENT SERVICES IN GERMANY – A SURVEY AMONG OFFICE-BASED PHYSICIANS
	Prenzler A¹, Mittendorf T¹, Kuchenbecker U², Montag T³, Mueller-Busch C⁴ ¹Leibniz University of Hannover, Hannover, Germany, ²Wyeth Pharma, Muenster, Germany, ³University hospital of Cologne, Cologne, Germany, ⁴German Association of Palliative Medicine, Berlin, Germany

PHP50	WITHDRAWN

PHP51	ASSESSMENT OF PRESCRIPTION DRUG KNOWLEDGE AND THE IMPACT OF COUNSELING ON IT IN PATIENTS VISITING A PUBLIC TEACHING HOSPITAL IN NORTH INDIA
	Kachhadiya R¹, Ethiraj D¹, Tiwari P², Gautam C³ ¹NIPER, Mohali, Punjab, India, ²NIPER, Mohali, India, Mohali, Punjab, India, ³Government Medical College and Hospital, Chandigarh, Punjab, India

PHP52	AN EVALUATION OF THE POLICY AND THE PROCEDURES OF SUCCESSFUL PHARMACEUTICAL EXPORTERS AND THE COMPARISON IRANIAN COUNTERPART POLICY
	Seyedifar/Meysam MS Tehran University of Medical Science, Tehran, Iran, Iran

PHP53	APPROPRIATE CLASSIFICATION OF HOSPITAL INFUSION SERVICES: MEDICARE REIMBURSEMENT CONSIDERATIONS
	Pierce CA The Resource Group, Richfield, OH, USA

PHP54	WITHDRAWN


PHP55	RECOMMENDATIONS FOR ORPHAN DRUGS IN TWO EU MEMBER STATES – A FOCUS ON THE UNDERLYING PHARMACOECONOMIC EVALUATIONS
	Vegter S¹, Postema R¹, Tolley KH², Postma MJ¹ ¹University of Groningen, Groningen, The Netherlands, ²Tolley Health Economics Limited, Buxton, Derbyshire, UK

PHP56	THE ROLE OF PHARMACOECONOMICS IN DRUG REIMBURSEMENT DECISION-MAKING IN THE NETHERLANDS
	Franken M, Koopmanschap M Erasmus University Medical Center, Rotterdam, The Netherlands

PHP57	GLOBAL PRICING AND REIMBURSEMENT (P & R) TRENDS: FURTHER DEVELOPMENTS IN SUPPLY AND DEMAND SIDE CONTROLS FOR MEDICINES
	Mallinson M, Gannedahl A Double Helix Consulting, London, UK

PHP58	MEDICARE DRUG PAYMENT AND PHARMACY HANDLING COSTS: HOW FAR HAVE WE COME?
	Pierce CA¹, Ziskind M² ¹The Resource Group, Richfield, OH, USA, ²Centocor Ortho Biotech, Inc, Horsham, PA, USA

PHP59	TRENDS IN COMPARATIVE EFFECTIVENESS OF TOP 20 HIGHEST SELLING DRUGS
	Aggarwal S, White N, Stevens C PAREXEL INTERNATIONAL, Bethesda, MD, USA

PHP60	PRICING AND REIMBURSEMENT (P&R) IN BRIC COUNTRIES
	Shepelev J, Richard L GfK Healthcare, London, UK

PHP61	POSITIVE DRUG LIST IN BULGARIA - 5 YEARS LATER
	Ivanova AD¹, Petrova GI¹, Benisheva - Dimitrova TV² ¹Medical University, Faculty of Pharmacy, Sofia, Bulgaria, ²Medical University Sofia, Faculty of Public Health, Sofia, Bulgaria

HEALTH CARE USE & POLICY STUDIESHealth Care Research & Education
PHP62	FREE BUT VALUABLE: THE ECONOMIC SIGNIFICANCE OF SERVICES PROVIDED BY PORTUGUESE PHARMACIES
	Gouveia M¹, Machado F¹, Mendes Z² ¹FCEE, Universidade Católica Portuguesa, Lisbon, Portugal, ²CEFAR- Center for Health Evaluation Studies, Lisbon, Portugal

PHP63	CONSENSUS OF KEY DECISION MAKERS AND EXPERTS ON THE PRESENT AND FUTURE ON THE ASSESSMENT OF HEALTH TECHNOLOGIES IN SPAIN
	Paz S¹, Lizan L², Rodriguez JM³, Anton E³ ¹Outcomes'10 Research Group, Castellon, Castellon, Spain, ²Jaume I University, Castellon, Spain, ³Medtronic Iberia, Madrid, Spain

PHP64	QUALITY ADJUSTED LIFE YEARS (QALYS) IN ECONOMIC EVALUATIONS OF HEALTH TECHNOLOGIES IN SPAIN: A REVIEW OF THE 2003-2009 LITERATURE
	Lizan Tudela LV¹, Paz S², Rodriguez JM³, González P³ ¹Jaune I Unversity, Castellon de la Plana, Castellon, Spain, ²Outcomes'10 Research Group, Castellon, Castellon, Spain, ³Medtronic Iberia, Madrid, Spain

PHP65	PUBLICATION OF COST-EFFECTIVENESS ANALYSES AND SUBSEQUENT CITATIONS IN THE MEDICAL AND HEALTH ECONOMICS LITERATURE
	Greenberg D¹, Wacht O², Neumann PJ¹ ¹Tufts Medical Center, Boston, MA, USA, ²Ben-Gurion University of the Negev, Beer-Sheva, Israel

PHP66	COST-EFFECTIVENESS RESEARCH ON PREVENTIVE MEASURES: A SURVEY OF THE PUBLICATIONS IN 2008
	van Gils P¹, Tariq L², Verschuuren M¹, Van den Berg M¹ ¹National Institute for Public Health and the Environment, Bilthoven, The Netherlands, ²National Institute of Public Health and the Environment, Bilthoven, The Netherlands

PHP67	THE PROBLEM-BASED LEARNING AS A NEW PRACTICAL METHOD OF SKILL DEVELOPMENT IN THE HEALTH SCIENCES HIGHER EDUCATION
	Szögedi-Müller I¹, Boncz I², Betlehem J², Fekete J¹, Kriszbacher I², Domján P¹ ¹University of Pécs, Zalaegerszeg, Hungary, ²University of Pécs, Pécs, Hungary

PHP68	FIRST IMPRESSIONS FROM A SHORT TRAINING COURSE IN RATIONAL USE OF DRUGS FOR THE PHARMACOLOGISTS IN THE PHARMACY SCHOOLS IN TURKEY
	Toklu HZ¹, Dulger G¹, Yaris E², Gumusel B³, Akici A⁴ ¹Marmara University School of Pharmacy, Istanbul, Turkey, ²Karadeniz Technical University School of Medicine, Trabzon, Turkey, ³Hacettepe University School of Pharmacy, Ankara, Turkey, ⁴Marmara University School of Medicine, Istanbul, Turkey

HEALTH CARE USE & POLICY STUDIESHealth Technology Assessment Programs
PHP69	DOES THE PROCEDURE MATTER? DIFFERENCES IN THE FUNDING OF DRUGS AND MEDICAL SERVICES IN AUSTRALIA
	Gallego G, Casey R, Norman R, Goodall S University of Technology, Sydney, Ultimo, NSW, Australia

PHP70	WITHDRAWN


PHP71	A COMPARISON OF HTA RECOMMENDATIONS ISSUED BY AGENCY FOR HEALTH TECHNOLOGY ASSESSMENT (AHTAPOL) IN POLAND AND THE SCOTTISH MEDICINES CONSORTIUM (SMC)
	Kolasa K AstraZeneca, Sodertalje , Sweden

PHP72	A REVIEW OF PHARMACOECONOMIC EVALUATIONS OF NEW AND EXISTING TECHNOLOGIES BY THE NATIONAL CENTRE FOR PHARMACOECONOMICS IN IRELAND
	Tilson L, O'Leary A, Usher C, Barry M National Centre for Pharmacoeconomics, Dublin, Ireland

PHP73	APPLYING KEY PRINCIPLES FOR IMPROVED HEALTH TECHNOLOGY ASSESSMENT: AN ANALYSIS OF 14 HTA ORGANIZATIONS
	Neumann PJ¹, Drummond MF², Jönsson B³, Luce B⁴, Schwartz JS⁵, Siebert U⁶, Sullivan SD⁷ ¹Tufts Medical Center, Boston, MA, USA, ²University of York, York, N. Yorkshire, UK, ³Stockholm School of Economics, Stockholm, Sweden, ⁴United BioSource Corporation, Bethesda, MD, USA, ⁵University of Pennsylvania, Merion Stn, PA, USA, ⁶UMIT - University for Health Sciences, Hall in Tyrol, Austria, ⁷University of Washington, Seattle, WA, USA

PHP74	ELECTROMAGNETIC INTERFERENCES BETWEEN WIRELESS COMMUNICATION TECHNOLOGY AND CRITICAL CARE MEDICAL EQUIPMENT: A HEALTH TECHNOLOGY ASSESSMENT
	Bouza C¹, Sastre M¹, Saz-Parkinson Z², Amate JM² ¹Carlos III Health Institute, Madrid, Spain, ²Instituto de Salud Carlos III, Madrid, Spain

PHP75	SCANNING THE HORIZON FOR NEW AND EMERGING OMIC TECHNOLOGIES
	Benguria-Arrate G, Gutierrez-Ibarluzea I, Ibargoyen-Roteta N, Galnares-Cordero L Basque Office for Health Technology Assessment, Vitoria-Gasteiz, Araba, Spain

PHP76	DESIGN AND TESTING OF AN INDICATOR (FINANCIAL BIAS INDICATOR - FBI)) THAT ESTIMATES THE INFLUENCE OF FUNDING IN THE RESULTS (FINANCING BIAS - FB)) OF ECONOMIC EVALUATIONS OF HEALTH TECHNOLOGIES (EEHT)
	Canon O¹, Bueno J², Oviedo E³, Giraldo V² ¹Investigaciones para la salud y la equidad, Bogotá, Colombia, ²Investigaciones para la salud y la equidad, Bogota, Colombia, ³Universidad Nacional De Colombia, Bogota, Colombia

PHP77	NEW DRUGS EVALUATION IN SPAIN: THE JOINT COMMITTEE OF NEW DRUGS EVALUATION EXPERIENCE
	Collar JM Grunenthal Pharma, S.A., Madrid, Spain

PHP78	THE ROLE OF HTA AGENCY IN DRUG REIMBURSEMENT DECISION-MAKING PROCESS IN POLAND (HTA IMPACT)
	Kolasa K AstraZeneca, Sodertalje , Sweden

PHP79	A REVIEW OF THE USE OF PROS IN SUBMISSIONS TO NICE
	Lenderking WR United BioSource Corporation, Lexington, MA, USA

PHP80	CLINICAL EFFECTIVENESS OF PORTABLE ULTRASOUND IN SMALL EMERGENCY DEPARTMENTS: A SYSTEMATIC REVIEW
	Gaebel K, Kaulback K, Robertson D, Blackhouse G, Xie F, Assasi N, Goeree R McMaster University, Hamilton, ON, Canada

HEALTH CARE USE & POLICY STUDIESPopulation Health
PHP81	USE OF SELF-REPORTED HEALTH STATUS TO PREDICT EMPLOYEE MEDICAL EXPENDITURES
	Huse D, Lenhart G Thomson Reuters, Cambridge, MA, USA

PHP82	ASSESSMENT OF LIFESPAN AND HEALTH STATUS EXPECTATIONS IN HUNGARY; RESULTS OF A WEB-SURVEY
	Péntek M¹, Brodszky V², Gulácsi LÁ², Érsek K², Exel NJA³, Brouwer WBF³, Gulácsi L² ¹Flor Ferenc County Hospital, Kistarcsa, Hungary, ²Corvinus University of Budapest, Budapest, Hungary, ³ErasmusMC, Rotterdam, The Netherlands

HEALTH CARE USE & POLICY STUDIESRegulation of Health Care Sector
PHP83	WITHDRAWN


PHP84	REGIONAL DIFFERENCES IN ACUTE CARE HOSPITAL BED CAPACITIES FOLLOWING THE 2006-2008 HEALTH CARE REFORM IN HUNGARY
	Vas G¹, Ágoston I¹, Nagy Z², Sebestyén A³, Kriszbacher I¹, Betlehem J¹, Varga S¹, Boncz I¹ ¹University of Pécs, Pécs, Hungary, ²Health Insurance Supervisory Authority, Budapest, Hungary, ³National Health Insurance Fund Administration, Pécs, Hungary

PHP85	WITHDRAWN

PHP86	ADHERENCE OF PHARMACOECONOMIC STUDIES SUBMITTED FOR THE REIMBURSEMENT AND PRICING SYSTEM IN 2008 TO THE CZECH PHARMACOECONOMIC GUIDELINES
	Petrikova A¹, Dolezal T², Suchankova E³ ¹University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic, ²Charles University, Praha, Czech Republic, ³Charles University, Prague, Czech Republic

HEALTH CARE USE & POLICY STUDIESBeyond Drug Interventions
PHP87	COST-EFFECTIVENESS OF HEALTH PROMOTING INTERVENTIONS
	De Smedt D¹, Bakker M¹, Annemans L² ¹University of Ghent, Gent, Belgium, ²University of Ghent, Brussels University, Ghent, Belgium

PHP88	HOW DOES THE HEALTH IMPROVEMENT NETWORK (THIN) DATA ON PREVALENCE OF CHRONIC DISEASES COMPARE WITH NATIONAL FIGURES?
	Blak BT, Thompson M CSD EPIC, London, UK

PHP89	ARE INCREMENTAL BENEFITS FROM MEDICAL CARE DECREASING? AN ANALYSIS OF QALY GAINS OVER TIME
	Greenberg D, Cohen JT, Neumann PJ Tufts Medical Center, Boston, MA, USA

PHP90	PATIENT- HEALTHCARE PROVIDER COMMUNICATION: IMPACT ON PATIENT SATISFACTION ON THE QUALITY OF HEALTH SERVICE
	Layton MR¹, Kerr SJ² ¹Khon Kaen University, Khon Kaen, Thailand, ²HIV-The Netherlands-Australia-Thailand Research Collaboration, Bangkok, Thailand

PHP91	IMPLANTABLE LOOP RECORDERS IN UNEXPLAINED TRANSIENT LOSS OF CONSCIOUSNESS (T-LOC) DIAGNOSTICS: A COST-SAVING OPPORTUNITY FOR THE UK NATIONAL HEALTH SERVICE (NHS)
	Petkar S¹, Tsintzos S², Brown B² ¹Manchester Royal Infirmary, Manchester, England, UK, ²Medtronic International Trading Sarl, Tolochenaz, Vaud, Switzerland

PHP92	COMPARISON OF THE TIME TO PREPARE CONTRAST MEDIA INJECTION IN CT SCAN EXAM WITH PREFILLED SYRINGES AND BOTTLES IN 7 EUROPEAN COUNTRIES
	Lafuma A¹, Mara Y² ¹Cemka, Bg la reine, Hauts de Seine, France, ²COVIDIEN AG, Zurich, Switzerland

PHP93	POTENTIAL COST-SAVINGS USING IMPLANTABLE LOOP RECORDERS (ILRS) FOR UNEXPLAINED SYNCOPE DIAGNOSTICS: THE CASE FOR THE NETHERLANDS
	Van Genugten M¹, Tsintzos S² ¹Medtronic EOC, Heerlen, The Netherlands, ²Medtronic International Trading Sarl, Tolochenaz, Vaud, Switzerland

PHP94	ASSESSMENT OF SHORT AND LONG TERM INGUINAL HERNIA RECURRENCE CASES AFTER HEAVY WEIGHT MESH DEVICE UTILIZATION UNDER PUBLIC HEALTHCARE SYSTEM PERSPECTIVE IN BRAZIL. WILL THE NEW TECHNOLOGIES IMPROVE THE SURGICAL OUTCOMES?
	Baran R¹, Nasciben VD² ¹Johnson & Johnson Medical Brasil, Sao Paulo, SP, Brazil, ²Johnson & Johnson Medical Brasil, São Paulo, SP, Brazil

PHP95	MEDICAL FOODS AND FOODS FOR SPECIAL MEDICAL PURPOSES
	Noe L¹, Neil N¹, Ogden K¹, Turini M² ¹ICON Clinical Research, San Francisco, CA, USA, ²ICON Clinical Research, Milan, Italy

PHP96	ALANYL-GLUTAMINE DIPEPTIDE (DIPEPTIVEN®) IN TOTAL PARENTERAL NUTRITION (TPN) THERAPY IN CRITICALLY ILL ITALIAN PATIENTS: A PHARMACOECONOMIC SIMULATION MODEL
	Eandi M¹, Pradelli L², Iannazzo S² ¹Università di Torino, Torino, Italy, ²AdRes HE&OR, Torino, Italy

PHP97	THE PHARMACOECONOMIC ANALYSIS OF EXTEMPORAL MEDICINES USED FOR TREATMENT OF DISEASES AT CHILDREN IN UKRAINE
	Zalis'ka O¹, Maynych J² ¹Danylo Halytsky Lviv national medical university, Lviv, Ukraine, ²Lviv National Medical University named Danylo Galitsky, Lviv, Ukraine

PHP98	COSTS OF BLEEDING RELATED COMPLICATIONS AND BLOOD PRODUCT TRANSFUSIONS AMONG SURGICAL PATIENTS
	Stokes ME¹, Shah M², Williams K³, Reynolds MW³, Rupnow MF⁴, Hammond J⁴ ¹United BioSource Corporation, Dorval, QC, Canada, ²Xcenda, Palm Harbor, FL, USA, ³United BioSource Corporation, Lexington, MA, USA, ⁴Ethicon, Inc, Somerville, NJ, USA

PHP99	A SYSTEMATIC REVIEW EVALUATING COST-EFFECTIVENESS OF ACUPUNCTURE
	Kim SY, Lee H, Park HJ Kyung Hee University, Seoul, South Korea

PHP100	WITHDRAWN

POSTER PRESENTATIONS SESSION I
SET-UP:	Sunday, 25 October, 11:30 – 12:00
POSTER DISPLAY HOURS:	Sunday, 25 October, 12:00 – 19:30
POSTER AUTHOR DISCUSSION HOUR:	Sunday, 25 October, 17:30 – 18:30
DISMANTLE:	Sunday, 25 October, 19:30 – 20:00

Cancer Clinical Outcomes Studies
PCN1	BURDEN OF THROMBOCYTOPENIA IN CANCER PATIENTS UNDERGOING CHEMOTHERAPY, 2000-2007
	Nalysnyk L¹, Wu Y², Aravind S³, Ranganathan G¹ ¹United BioSource Corporation, Lexington, MA, USA, ²Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA, USA, ³Johnson & Johnson Pharmaceutical Services, LLC, New Brunswick, MA, USA

PCN2	DOSE DELAY AMONGST CANCER PATIENTS UNDERGOING CHEMOTHERAPY
	Nalysnyk L¹, Wu Y², Aravind S³, Ranganathan G¹ ¹United BioSource Corporation, Lexington, MA, USA, ²Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA, USA, ³Johnson & Johnson Pharmaceutical Services, LLC, New Brunswick, MA, USA

PCN3	HEAD AND NECK CANCER PATIENTS AT INCREASED RISK OF COMORBIDITY COMPARED TO CANCER-FREE CONTROLS
	van Herk-Sukel M¹, Landis SH², van den Haak P¹, Janssen-Heijnen ML³, El-Hariry IA², Penning-van Beest F¹, Herings RMC¹ ¹PHARMO Institute, Utrecht, Utrecht, The Netherlands, ²GlaxoSmithKline, Greenford, UK, ³Eindhoven Cancer Registry, Eindhoven, The Netherlands

PCN4	BISPHOSPHONATES AND TIME TO OSTEONECROSIS DEVELOPMENT. A SYSTEMATIC REVIEW
	Palaska PK¹, Cartsos V², Zavras A¹ ¹Harvard University, Boston, MA, USA, ²Tufts University, Boston, MA, USA

PCN5	RENAL CELL CARCINOMA PATIENTS ARE TWICE AS LIKELY TO DEVELOP THROMBOEMBOLIC EVENTS COMPARED TO CANCER-FREE CONTROLS
	van Herk-Sukel MPP¹, Shantakumar S², Casparie MK³, Abrahamson PE⁴, Penning-van Beest FJA¹, Herings RMC¹ ¹PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, ²GlaxoSmithKline, Research Triangle Park, NC, USA, ³PALGA, Utrecht, The Netherlands, ⁴Salmon Bay Epidemiology, Seattle, WA, USA

PCN6	A COMPARISON OF CLINICAL EFFICACY AND SAFETY OF LENOGRASTIM AND FILGRASTIM IN THE STEM CELL MOBILIZATION
	Pankiewicz O¹, Rogoz A¹, Rys P¹, Lis J², Gierczynski J², Plisko R¹, Wladysiuk M¹ ¹HTA Consulting, Krakow, Poland, ²Sanofi-Aventis, Warsaw, Poland

PCN7	A COMPARISON OF CLINICAL EFFICACY AND SAFETY OF PERIPHERAL BLOOD STEM CELL TRANSPLANTATION AFTER MOBILIZATION WITH LENOGRASTIM AND FILGRASTIM
	Pankiewicz O¹, Rogoz A¹, Rys P¹, Lis J², Gierczynski J², Plisko R¹, Wladysiuk M¹ ¹HTA Consulting, Krakow, Poland, ²Sanofi-Aventis, Warsaw, Poland

PCN8	COMORBIDITIES IN PATIENTS WITH METASTATIC COLORECTAL CANCER
	Fu AZ¹, Zhao Z², Wang PF², Barber B², Liu G³ ¹Cleveland Clinic, Cleveland, OH, USA, ²Amgen, Inc., Thousand Oaks, CA, USA, ³Peking University, Beijing, Beijing, China

PCN9	DEVELOPMENT OF SERUM TESTS FOR COLORECTAL CANCER SCREENING
	Schiff L¹, Foster T¹, Junker F², Vogel-Ziebolz S³, Pashos CL¹, Creeden J⁴ ¹Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, ²Roche Diagnostics AG, Rotkreuz, Switzerland, ³Roche Diagnostics, Penzberg, Germany, ⁴Roche Diagnostics, Ltd, Rotkreuz, Switzerland

PCN10	MALIGNANT GASTROINTESTINAL STROMAL TUMORS TREATED WITH IMATINIB IN FRANCE: EFFICACY IN REAL LIFE
	Blay JY¹, Bouché O², Cucherat M³, Goldberg M⁴, Grosclaude P⁵, Sambuc R⁶, Bisot-Locard S⁷, Deschaseaux C⁷, Sailly J⁸ ¹Centre Léon Bérard, Lyon, France, ²Robert Debré Hospital, Reims, France, ³Laennec University, Lyon, France, ⁴INSERM, Villejuif, France, ⁵Tarn Cancer registry, Albi, France, ⁶University of Aix-Marseille II, Faculty of Medicine, Marseille, France, ⁷Novartis Pharma, Rueil malmaison, France, ⁸CRESGE, Wattignies, France

PCN11	INDIRECT COMPARISON TO ESTIMATE THE EFFICACY OF INTERVENTIONS IN TREATMENT OF METASTATIC RENAL CELL CARCINOMA: A MIXED TREATMENT COMPARISON
	Bonthapally V¹, Ghosh S², Rappaport H³ ¹University of Louisiana at Monroe, Monroe, LA, USA, ²Independent, West Monroe, LA, USA, ³The University of Louisiana at Monroe, Monroe, LA, USA

PCN12	EXPLORING THE ROLE OF OUTCOMES RESEARCH IN DUTCH REIMBURSEMENT POLICY: REAL-WORLD PHARMACOECONOMICS OF OXALIPLATIN IN STAGE III COLON CANCER
	van Gils CWM¹, Redekop WK¹, Punt CJA², Uyl-de Groot CA¹ ¹Erasmus University Medical Center, Rotterdam, The Netherlands, ²University Medical Center St Radboud, Nijmegen, The Netherlands

PCN13	A COMPARATIVE EFFECTIVENESS ASSESSMENT OF FIRST-LINE BEVACIZUMAB + INTERFERON ALPHA-2A VS SUNITINIB IN METASTATIC RENAL CELL CARCINOMA
	Mickisch GH¹, Schwander B², Escudier B³, Bellmunt J⁴, Maroto P⁵, Porta C⁶, Walzer S⁷, Siebert U⁸ ¹Center of Operative Urology Bremen, Bremen, Germany, ²AiM GmbH Assessment in Medicine, Schopfheim, Germany, ³Institut Gustave Roussy, Villejuif, France, ⁴University Hospital del Mar. UPF, Barcelona, Spain, ⁵Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁶IRCCS San Matteo University Hospital Foundation, Pavia, Italy, ⁷F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland, ⁸UMIT – University for Health Sciences, Medical Informatics and Technology, Hall i.T, Austria

PCN14	AN INDIRECT COMPARISON OF THE EFFICACY OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) OR BEVACIZUMAB PLUS CARBOPLATIN AND PACLITAXEL (BCP) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
	Walzer S¹, de Castro Carpeño J², Vergnenegre A³, Chouaid C⁴, Heigener D⁵, Bischoff HG⁶, Aultman R⁷, Siebert U⁸ ¹F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland, ²Hospital Universitario de La Paz, Madrid, Spain, ³CHU Limoges, Limoges, France, ⁴Hopital saint antoine, Paris, France, ⁵Krankenhaus Grosshansdorf, Grosshansdorf, Germany, ⁶Thoraxklinik Heidelberg, Heidelberg, Germany, ⁷F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁸UMIT – University for Health Sciences, Medical Informatics and Technology, Hall i.T, Austria

PCN15	CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB IN FRANCE: EFFICACY IN REAL LIFE
	Guilhot F¹, Reiffers J², Rousselot P³, Sigaux F⁴, Cucherat M⁵, Goldberg M⁶, Grosclaude P⁷, Sambuc R⁸, Belanger C⁹, Deschaseaux C⁹, Sailly J¹⁰ ¹CHU La Miletrie, Poitiers, France, ²Institut Bergonie, Bordeaux, France, ³Andre Mignot Hospital, Le Chesnay, France, ⁴INSERM, Paris, France, ⁵Laennec University, Lyon, France, ⁶INSERM, Villejuif, France, ⁷Tarn Cancer registry, Albi, France, ⁸University of Aix-Marseille II, Faculty of Medicine, Marseille, France, ⁹Novartis Pharma, Rueil malmaison, France, ¹⁰CRESGE, Wattignies, France

PCN16	EVALUATION OF THE EFFICACY OF THE POPULATION-BASED CERVICAL CANCER SCREENING IN HUNGARY
	Pakai A¹, Németh K¹, Kriszbacher I¹, Dér A¹, Lampek K¹, Boncz I¹, Zsigmond E¹, Balázs P² ¹University of Pécs, Pécs, Hungary, ²Semmelweis University, Budapest, Hungary

PCN17	SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF IMIQUIMOD 5% CREAM FOR THE TREATMENT OF SUPERFICIAL BASAL CELL CARCINOMA
	Walczak J, Nogas G, Chmiel M, Kowalska M Arcana Institute, Cracow, Poland

PCN18	OUTCOMES RESEARCH OF BORTEZOMIB INDICATED FOR MULTIPLE MYELOMA IN THE CONTEXT OF THE DUTCH REIMBURSEMENT POLICY FOR EXPENSIVE MEDICINES: THREATS TO THE INTERNAL VALIDITY OF THE INCREMENTAL EFFECTIVENESS ESTIMATE
	Gaultney J¹, Franken M¹, van Gils CWM¹, Huijgens P², Redekop WK¹, Uyl-de Groot CA¹ ¹Erasmus University Medical Center, Rotterdam, The Netherlands, ²VU University Medical Centre, Amsterdam, The Netherlands

PCN19	A LITERATURE REVIEW ON THE CLINICAL AND ECONOMIC OUTCOMES ATTRIBUTABLE TO FIRST-LINE TREATMENT FOR CHRONIC MYELOID LEUKAEMIA (CML) WITH IMATINIB MESYLATE AND BONE MARROW TRANSPLANTATION (BMT)
	Sladkevicius E¹, Coombs J², Guest JF¹ ¹Catalyst Health Economics Consultants, Northwood, Middlesex, UK, ²Novartis Pharmaceuticals, East Hanover, NJ, USA

PCN20	REAL LIFE TREATMENT DURATION OF SORAFENIB OR SUNITINIB IN FIRST LINE METASTATIC RENAL CELL CARCINOMA PATIENTS- A COMPARATIVE ANALYSIS
	Hammerman A, Klang SH, Liebermann N Clalit Health Services, Tel-Aviv, Israel

PCN21	NUMBER NEEDED TO TREAT (NNT) ANALYSIS COMPARING BENEFITS OF LETROZOLE WITH ADJUVANT CHEMOTHERAPY IN PATIENTS WITH NODE-POSITIVE BREAST CANCER
	Dhillon N¹, Kaura S², Dranitsaris G³, Rugo H¹ ¹University of California at San Francsico (UCSF), San Francisco, CA, USA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, ³Augmentium Pharma Consulting, Toronto, ON, Canada

PCN22	COMPARING THE SURVIVAL BENEFIT OF LETROZOLE AND ANASTROZOLE: A NUMBER NEEDED TO TREAT ANALYSIS
	Rugo H¹, Kaura S², Dranitaris G³ ¹University of California at San Francsico (UCSF), San Francisco, CA, USA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, ³Augmentium Pharma Consulting, Toronto, ON, Canada

PCN23	PHARMACOEPIDEMIOLOGY OF PATIENTS TREATED WITH TEMOZOLOMIDE
	Brignone M¹, Borget I², Hassani Y³, Bertholle V⁴, Billard M⁴, Lefebre MN⁵, Schlemmer C⁵, Charlety D⁶, Audeval C⁷, Raingeard E⁷, Daouphars M⁸, Pinguet F⁹, Fabbro M⁹, Chevrier R¹⁰, Tilleul P¹¹ ¹St-Antoine Hospital, Paris, France, ²Institut de Cancérologie Gustave Roussy, Villejuif, France, ³Saint-Antoine Hospital, Pharmacy, Paris , France, ⁴CHU Lyon, Lyon, France, ⁵CHRU de Lille, Lille, France, ⁶CHU Grenoble, Grenoble , France, ⁷Institut Gauducheau, Saint-Herblain, France, ⁸Pharmacy CLNCC, Rouen, Rouen , France, ⁹Pharmacy CRLCC, Montpellier, France, Montpellier, France, ¹⁰Jean Perrin, Clermont-Ferrand, France, ¹¹St-Antoine Hospital and Pharmacy University Paris-Descartes, Paris, Paris, France

PCN24	CLINICAL OUTCOMES AND HEALTH CARE RESOURCE UTILISATION OF PATIENTS RECEIVING LAPATINIB FOR BREAST CANCER IN FRANCE: THE LAPS STUDY (LAPATINIB ATU PARCOURS DE SOINS)
	Perrocheau G¹, Tehard B², Terpereau A², Campone M³ ¹Centre Renée Gauducheau, Saint Herblain, France, ²GlaxoSmithKline, Marly-le-Roi, France, ³Centre René Gauducheau, Saint Herblain, France

PCN25	HALF OF BREAST CANCER PATIENTS STARTING ON TAMOXIFEN COMPLETE FIVE YEARS OF ENDOCRINE TREATMENT
	van Herk-Sukel MPP¹, Voogd AC², Nieuwenhuijzen GAP³, Herings RMC¹, Coebergh JWW⁴, Van de Poll-Franse LV⁴ ¹PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, ²Maastricht University, Maastricht, The Netherlands, ³Catharina Hospital, Eindhoven, The Netherlands, ⁴Eindhoven Cancer Registry, Eindhoven, The Netherlands

PCN26	RELATIVE IMPACT OF SCREENING AND THERAPEUTIC PROGRESS ON THE REDUCTION OF BREAST CANCER SPECIFIC MORTALITY IN FRANCE: A SIMULATION MODEL OVER THE PERIOD 1994-2005
	Bouee S¹, Fagnani F¹, Alfonsi A², Florentin V² ¹CEMKA-EVAL, Bourg la Reine, France, ²Roche, Neuilly sur Seine, France

PCN27	TRENDS IN COLORECTAL CANCER SCREENING (CRC) PATTERNS AMONG COMMUNITY DWELLING MEDICARE BENEFICIARIES
	Maneno M¹, Lee E¹, Zuckerman IH², Simoni-Wastila L², Daniel M¹, Green PM³, Adderley-Kelly B³, Wutoh AK⁴ ¹Center for Minority Health Services Research, Dept of Clinical & Administrative Pharmacy Sciences, Howard University, Washington, DC, USA, ²Department of Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland, Baltimore, MD, USA, ³College of Pharmacy, Nursing, and Allied Health Science, Howard University, Washington, DC, USA, ⁴Center for Minority Health Services Research, Dept of Clinical & Administrative Pharmacy Sciences, Howard University, Washington , DC, USA

PCN28	INCIDENCE AND PREVALENCE OF CUTANEOUS MELANOMA IN FRANCE : A POPULATION BASED STUDY FROM EIGHT CANCER REGISTRIES
	Binder-Foucard F¹, Olteanu S¹, Levrat F², Danzon A³, Guizard AV⁴, Bara S⁵, Colonna M⁶, Grosclaude P⁷, Lapôtre-Ledoux B⁸, Molinié F⁹, Tretarre B¹⁰, Hédelin G¹¹, Velten M¹² ¹Bas-Rhin cancer registry, Strasbourg, France, ²Pfizer, Paris, France, ³Doubs cancer registry, Besançon, France, ⁴Calvados cancer registry, Caen, France, ⁵Manche cancer registry, Cherbourg, France, ⁶Isere cancer registry, Meylan, France, ⁷Tarn Cancer registry, Albi, France, ⁸Somme cancer registry, Amiens , France, ⁹Loire Atlantique and Vandée cancer registry, Nantes, France, ¹⁰Herault cancer registry, Montpelliers, France, ¹¹Bas Rhin cancer registry, strasbourg, France, ¹²Universite Louis Pasteur, strasbourg, France

PCN29	PATTERNS OF COLORECTAL CANCER SCREENING AND OBESITY AMONG MEDICARE BENEFICIARIES
	Kendall KA¹, Lee E², Zuckerman IH³, Simoni-Wastila L⁴, Daniel M⁵, Green PM⁶, Adderley-Kelly B⁶, Wutoh AK⁷ ¹Howard University, Washington, DC, USA, ²Howard University School of Pharmacy, Washington, DC, USA, ³University of Maryland School of Pharmacy, Baltimore, MD, USA, ⁴University of Maryland, Baltimore, MD, USA, ⁵Center for Minority Health Services Research, Dept of Clinical & Administrative Pharmacy Sciences, Howard University, Washington , DC, USA, ⁶College of Pharmacy, Nursing, and Allied Health Science, Howard University, Washington, DC, USA, ⁷Center for Minority Health Services Research, Dept of Clinical & Administrative Pharmacy Sciences, Howard University, Washington, DC, USA

PCN30	THE BURDEN OF MULTIPLE MYELOMA: ASSESSMENT ON OCCURRENCE, OUTCOMES AND COST USING A RETROSPECTIVE LONGITUDINAL STUDY BASED ON ADMINISTRATIVE CLAIMS DATABASE
	de Portu S¹, Fanin R², Patriarca F², Morsanutto A³, Tosolini F³, Esti R³, Mantovani LG¹ ¹University Federico II, Naples, Italy, ²University of Udine, Udine, Italy, ³Friuli Venezia Giulia Regional Health Authority, Trieste, Italy

PCN31	A DESCRIPTIVE ANALYSIS OF THE ASSOCIATION BETWEEN BREAST CANCER RISK, BONE MINERAL DENSITY AND FRACTURES IN POST-MENOPAUSAL WOMEN IN THE CANADIAN MULTICENTRE OSTEOPOROSIS STUDY
	Ioannidis G¹, Adachi J¹, Burge RT², Papadimitropoulos M³, Krege JH², Stock JL², Muram D² ¹McMaster University, Hamilton, ON, Canada, ²Eli Lilly & Company, Indianapolis, IN, USA, ³Eli Lilly & Company, Toronto, ON, Canada

PCN32	IMPLEMENTATION OF CLINICAL INTERVENTION REPORTING SYSTEM FOR PHARMACISTS
	Kamal S Children Cancer Hospital, Cairo, Cairo, Egypt

PCN33	WITHDRAWN

CANCER Cost Studies
PCN34	BUDGET IMPACT ANALYSIS OF DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) IN BRAZIL
	Asano E¹, Nita M¹, Moellmann-Coelho A², Rached R¹, Donato B³, Rahal E¹ ¹Bristol-Myers Squibb S/A, São Paulo, São Paulo, Brazil, ²Instituto Nacional de Cancer (INCA), Rio de janeiro, Rio de Janeiro, Brazil, ³Bristol-Myers Squibb, Wallingford, CT, USA

PCN35	BUDGETARY IMPACT OF ORAL CHEMOTHERAPY: REAL-WORLD DATA ANALYSIS FROM PAYERS' PERSPECTIVES IN BRAZIL
	Clark O, Alves AF, Castro AP, Santos FS, Faleiros E, Clark LG, Paladini L, Pegoretti B, Engel T Evidencias Medicas, Campinas, SP, Brazil

PCN36	EVIDENCE-BASED MEDICINE (EBM) AND THE PROFILE OF APPEALS FOLLOWING AUDITING IN CHEMOTHERAPY TREATMENTS
	Alves AF¹, Castro AP¹, Clark LG², Clark O¹ ¹Evidencias Medicas, Campinas, SP, Brazil, ²Evidencias Medicas, Campinas, sp, Brazil

PCN37	EXPECTED ECONOMIC BURDEN OF TREATING ADVANCED SOFT TISSUE SARCOMAS WITH TRABECTEDIN IN RUSSIA
	Avxentyeva M, Vorobiev P Moscow Medical Academy named after I.M.Sechenov, Moscow, Russia

PCN38	NUMBER NEEDED TO TREAT (NNT) TO AVOID ONE GASTROINTESTINAL STROMAL TUMOUR (GIST) RECURRENCE IN BRAZIL. COST COMPARISON AND BUDGET IMPACT ANALYSIS OF ADJUVANT TREATMENT WITH IMATINIB
	Valentim J¹, Coombs J², Sakano A³, Puty F¹ ¹Novartis Biociências S.A, São Paulo, SP, Brazil, ²Novartis Pharmaceuticals, East Hanover, NJ, USA, ³University of São Paulo, São Paulo , SP, Brazil

PCN39	COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF USING TEMSIROLIMUS COMPARED TO INTERFERON ALPHA IN METASTATIC RENAL CELL CARCINOMA
	Bonthapally V¹, Ghosh S², Rappaport H¹ ¹University of Louisiana at Monroe, Monroe, LA, USA, ²Independent, West Monroe, LA, USA

PCN40	COST OF MANAGING ADVERSE EVENTS IN THE TREATMENT OF FIRST LINE METASTASIC RENAL CELL CARCINOMA: BEVACIZUMAB + INTERFERON ALPHA-2A COMPARED WITH SUNITINIB IN SPAIN
	Calderero V¹, García-Muro X², Puente J³, Trigo JM⁴, Castro AJ⁵, Martín-Escudero V⁵, Yébenes M⁶, Casado MA⁶ ¹Hospital Universitario Miguel Servet, Zaragoza, Spain, ²Institut Català dOncologia, Barcelona, Spain, ³Hospital Clínico San Carlos, Madrid, Spain, ⁴Hospital Universitario Virgen de la Victoria, Málaga, Spain, ⁵Roche Farma, Madrid, Spain, ⁶Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain

PCN41	COST-SAVINGS ASSOCIATED WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY
	Heigener D¹, Bischoff HG², Wiesner C³ ¹Krankenhaus Grosshansdorf, Grosshansdorf, Germany, ²Thoraxklinik Heidelberg, Heidelberg, Germany, ³Roche Pharma AG, Grenzach-Wyhlen, Germany

PCN42	ECONOMIC EVALUATION OF THE USE OF HAEMOSTATIC SEALANT PATCH FOR PULMONARY LOBECTOMY PROCEDURE
	Droghetti A¹, Di Stasi F², Pantaleoni M³, Muriana G¹ ¹Carlo Poma Hospital, Mantova, Italy, ²Nycomed SpA, Milano, Italy, ³IMS Health, Milano, Italy

PCN43	THE COST OF TREATING GRADE 3/4 ADVERSE EVENTS RELATED TO FIRST-LINE THERAPY WITH BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE
	Chouaid C¹, Vergnenegre A², Brunner M³, Walzer S⁴ ¹Hopital Saint antoine, APHP, Paris, France, ²CHU Limoges, Limoges, France, ³Outcomes International, Basel, Switzerland, ⁴F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland

PCN44	WITHDRAWN

PCN45	COST COMPARISON BETWEEN 90Y IBRITUMOMAB TIUXETAN CONSOLIDATION AND RITUXIMAB MAINTENANCE POST-CHEMOTHERAPY IN NAÏVE PATIENTS WITH B-CELL NON-HODGKIN'S LYMPHOMA IN SPAIN
	Tomas JF¹, Febrer L², Piñol C², Musi E² ¹MD Anderson Cancer Center Spain, Madrid, Spain, ²Bayer HealthCare, Barcelona, Catalonia, Spain

PCN46	COST SAVINGS RELATED TO SUPERIOR ADVERSE EVENT PROFILE OF BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE IN THE FIRST-LINE THERAPY OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY: A SENSITIVITY ANALYSIS ON THE ECOG STATUS
	Heigener D¹, Bischoff HG², Banz K³, Walzer S⁴ ¹Krankenhaus Grosshansdorf, Grosshansdorf, Germany, ²Thoraxklinik Heidelberg, Heidelberg, Germany, ³Outcomes International, Basel, Switzerland, ⁴F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland

PCN47	COSTS OF TREATING SEVERE ADVERSE EVENTS OBSERVED WITH A REGIMEN OF BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE IN THE FIRST-LINE THERAPY OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY
	Bischoff HG¹, Heigener D², Banz K³, Walzer S⁴ ¹Thoraxklinik Heidelberg, Heidelberg, Germany, ²Krankenhaus Grosshansdorf, Grosshansdorf, Germany, ³Outcomes International, Basel, Switzerland, ⁴F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland

PCN48	COST OF CARE FOR COLORECTAL CANCER IN IRELAND: A HEALTH CARE PAYER PERSPECTIVE
	Tilson L¹, Sharp L², Walsh C³, O'Ceilleachair A², Usher C¹, Comber H², Barry M¹ ¹National Centre for Pharmacoeconomics, Dublin, Ireland, ²National Cancer Registry of Ireland, Cork, Ireland, ³Trinity College Dublin, Dublin, Ireland

PCN49	COSTS AND QUALITY OF LIFE OF MULTIPLE MYELOMA (MM) IN ITALY: THE CO.MI.M. STUDY
	Petrucci MT¹, Calabrese E¹, Levi A¹, Federico V¹, Ceccolini M², Rizzi R³, Gozzetti A⁴, Cavallo F⁵, Cavallo M⁶, Gerzeli S⁶, Boccadoro M⁵, Lauria F⁴, Liso V³, Cavo M², Foà R¹ ¹University La Sapienza, Rome, Italy, ²University of Bologna, Bologna, Italy, ³University of Bari, Bari, Italy, ⁴University of Siena, Siena, Italy, ⁵A.O.U. San Giovanni Battista, Torino, Italy, ⁶Bocconi University, Milano, Italy

PCN50	HOSPITALISATIONS FOR HEAD AND NECK CANCERS IN FRANCE
	Lacau St Guily J¹, Borget I², Vainchtock A³, Rémy V⁴ ¹Hôpital Tenon, Paris, France, ²Institut Gustave Roussy, Villejuif, France, ³HEVA, Lyon, France, ⁴Sanofi Pasteur MSD, Lyon, France

PCN51	THE COSTS OF BREAST CANCER PRIOR TO AND FOLLOWING DIAGNOSIS
	Broeckx S¹, Den Hond E¹, Torfs R¹, D'Hooghe T², Simoens S³ ¹Flemish Institute for Technological Research, Mol, Belgium, ²University Hospitals Leuven, Leuven, Belgium, ³Katholieke Universiteit Leuven, Leuven, Belgium

PCN52	COSTS OF ADVANCED GASTRIC CANCER (AGC) IN BRAZIL FROM THE PUBLIC PAYER PERSPECTIVE
	Clark O¹, Santos EA², Saggia MG² ¹Evidencias Medicas, Campinas, Sao Paulo, Brazil, ²Roche Brazil, Sao Paulo, SP, Brazil

PCN53	COST PER DISEASE STAGE OF ADVANCED GASTRIC CANCER IN BRAZIL FROM THE PRIVATE PAYER PERSPECTIVE
	Clark O¹, Santos EA², Saggia MG² ¹Evidencias Medicas, Campinas, Sao Paulo, Brazil, ²Roche Brazil, Sao Paulo, SP, Brazil

PCN54	A DESCRIPTIVE ANALYSIS OF SUBJECTS WITH METASTATIC GASTRIC CANCER (MGC)
	Oglesby AK¹, Lage MJ², Wang PF¹ ¹Amgen, Inc., Thousand Oaks, CA, USA, ²HealthMetrics Outcomes Research, LLC, Groton, CT, USA

PCN55	THE ECONOMIC EVALUATION OF SUNITINIB AND SORAFENIB IN MRCC PATIENTS IN THE CZECH REPUBLIC
	Demlova R¹, Ondrackova B², Kominek J¹ ¹Masaryk Memorial Cancer Institute, Brno, Czech Republic, ²Masaryk University, Brno, Czech Republic

PCN56	COST OF RENAL CELL CARCINOMA TREATMENT IN PATIENTS TREATED WITH INTERFERON-ALPHA
	Purmonen T¹, Vuorinen R², Kataja V³, Pyrhönen S⁴, Kellokumpu-Lehtinen P⁵ ¹University of Kuopio, Kuopio, Finland, ²University of Turku, Turku, Finland, ³Kuopio University Hospital and Vaasa Central Hospital, Kuopio, Finland, ⁴Turku University Hospital and University of Turku, Turku, Finland, ⁵Tampere University Hospital and University of Tampere, Tampere, Finland

PCN57	EVALUATION OF THE COMPLICATION RATE AND COST OF TREATMENT ACCORDING TO THE MASCC INDEX IN PATIENTS WITH FEBRILE NEUTROPENIA
	Borget I¹, Bonnet P², Gachot B², Di Palma M³, Antoun S¹, Merad M¹ ¹Institut de Cancérologie Gustave Roussy, Villejuif, France, ²Institut Gustave Roussy, Villejuif, France, ³Insitut Gustave Roussy, Villejuif, France

PCN58	RESOURCES USED IN PATIENTS WITH ANEMIA INDUCED BY CHEMOTHERAPY REQUIRING BLOOD TRANSFUSIONS. EPICOST STUDY, PRELIMINARY RESULTS (ONVIDA GROUP)
	Camps C¹, Casas A², Barón F³, Colmenarejo A⁴, Jara C⁵, Lobo F⁶, Massuti B⁷, Poveda JL⁸, Rifá J⁹, Sánchez-Maestre C¹⁰, Rubio-Terrés C¹¹ ¹Hospital General Universitario de Valencia, Valencia, Spain, ²Hospital Universitario Virgen del Rocio, Seville, Spain, ³Hospital Universitario Santiago de Compostela, Santiago de Compostela, La Coruña, Spain, ⁴Hospital Central de la Defensa, Madrid, Spain, ⁵Hospital Unversitario de Alcorcón, Alcorcón, Madrid, Spain, ⁶Hospital Fundcaión Jiménez Díaz, Madrid, Spain, ⁷Hospital General de Alicante, Alicante, Spain, ⁸Hospital Universitario La Fe, Valencia, Spain, ⁹Hospital Son Dureta, Palma de Mallorca, Balearic Islands, Spain, ¹⁰Roche, Madrid, Spain, ¹¹HERO Consulting, Madrid, Spain

PCN59	REAL-WORLD COSTS OF ADJUVANT TREATMENT FOR STAGE III COLON CANCER PATIENTS IN THE NETHERLANDS
	van Gils CWM¹, Tan SS², Redekop WK¹, Punt CJA³ ¹Erasmus University Medical Center, Rotterdam, The Netherlands, ²Erasmus MC University Medical Center, Rotterdam, The Netherlands, ³University Medical Center St Radboud, Nijmegen, The Netherlands
PCN60	TREATMENT COSTS ASSOCIATED WITH METASTATIC BREAST CANCER
	Park HJ, Ko S Pfizer Korea, Seoul, South Korea

PCN61	HOSPITAL BURDEN RELATED TO UPPER AERODIGESTIVE TRACT CANCERS IN FRANCE
	Cancalon C, Schmidt A, Bénard S ST[E]VE Consultants, Lyon, France

PCN62	COST ANALYSIS OF HORMONE RECEPTOR POSITIVE, ADVANCED BREAST CANCER TREATMENT WITH ENDOCRINE THERAPY VERSUS CHEMOTHERAPY IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM (BPHS)
	Abdo Filho E¹, Takemoto M², Teich VD², Quintella FF², Fernandes RA², Passos RBF², Teich N², Silva AP³, Marques M³, Mottola Jr J⁴, Gebrim LH⁴, Picinini SE⁴, Sakano M⁴ ¹Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil, ²MedInsight, Rio de Janeiro, Brazil, ³AstraZeneca, São Paulo, Brazil, ⁴Centro de Referência em Saúde da Mulher, São Paulo, Brazil

PCN63	REVIEW OF THE ECONOMIC IMPACT OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY
	Sasane M¹, Tencer T², Beusterien K³ ¹Oxford Outcomes Inc, Exton, PA, USA, ²Eisai Corporation, Woodcliff Lake, NJ, USA, ³Oxford Outcomes Inc, Bethesda, MD, USA

PCN64	CHARACTERIZING RESOURCE USE AND TREATMENT COSTS FOR CHRONIC MYELOGENOUS LEUKEMIA (CML) IN THE UNITED KINGDOM (UK)
	Szabo SM¹, Davis C², Sidhu S¹, Levy AR¹ ¹Oxford Outcomes Ltd, Vancouver, BC, Canada, ²Bristol-Myers Squibb, Wallingford, CT, USA

PCN65	INPATIENT COST AND REIMBURSEMENT FOR PATIENTS WITH PROGRESSIVE MALIGNANT THORACIC NEOPLASM IN GERMANY
	Krych M¹, Clouth J², Merito M³, Hoebel N³, Andraschko J¹, Kreyenberg K³, Ostermann H¹ ¹Ludwig-Maximilian University, Munich, Germany, ²Lilly Deutschland GmbH, Bad Homburg, Germany, ³Kendle GmbH, Munich, Germany

PCN66	COST EVALUATION OF THE CROSS PROTECTION DIFFERENCE BETWEEN THE BIVALENT AND QUADRIVALENT HPV VACCINE AGAINST CERVICAL CANCER WITHIN EUROPEAN COUNTRIES
	Capri S¹, Demarteau N², Standaert B² ¹Cattaneo-LIUC University, Castellanza, (Varese), Italy, ²GlaxoSmithKline Biologicals, Rixensart, Belgium

PCN67	LOWER ADMINISTRATION COSTS OF BEVACIZUMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY VERSUS CETUXIMAB-VINORELBINE-CISPLATIN THERAPY FOR THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) FOCUSING ON THREE EUROPEAN HEALTH CARE SYSTEMS
	Rosery H¹, Castro de C², Bischoff H³, Heigener D⁴, Vergnenegre A⁵, Chouaid C⁶, Walzer S⁷ ¹AiM GmbH Assessment-in-Medicine, Schopfheim, Germany, ²Hospital Universitario de La Paz, Madrid, Spain, ³Thoraxklinik Heidelberg gGmbH, Heidelberg, Germany, ⁴Krankenhaus Grosshansdorf, Grosshansdorf, Germany, ⁵University Hospital, Limoges, France, ⁶Hôpital Saint-Antoine, Paris, France, ⁷F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland

PCN68	US AND CANADIAN COST-EFFECTIVENESS ANALYSES OF US ONCOLOGY TRIAL 9735 PROVIDE ADDITIONAL RATIONALE FOR AVOIDING ANTHRACYCLINES IN THE ADJUVANT TREATMENT OF OPERABLE BREAST CANCER
	Chin C¹, Jones S², Verma S³, Bernard L⁴, Thompson MF⁵, Mittmann N⁶, Chan BCF⁷, Tangirala M⁸, Asmar L⁹ ¹sanofi-aventis Canada Inc., Laval, QC, Canada, ²US Oncology Research, Houston, TX, USA, ³The Ottawa Hospital Regional Cancer Centre, Ottawa, ON, Canada, ⁴Cornerstone Research Group Inc., Burlington, ON, Canada, ⁵Cornerstone Research Group Inc, Burlington, ON, Canada, ⁶Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ⁷HOPE Research Centre, Toronto, ON, Canada, ⁸Smith Hanley Consulting Group LLC, Lake Mary, FL, USA, ⁹US Oncology, Houston, TX, USA

PCN69	COST-EFFECTIVENESS OF ADDING CAPECITABINE TO TRASTUZUMAB AND DOCETAXEL AS FIRST LINE THERAPY FOR PATIENTS WITH HER-2-POSITIVE METASTATIC BREAST CANCER (HER2+MBC) – RESULTS FROM SPAIN, FRANCE AND ITALY
	Hieke K¹, Ducournau P², de Reydet de Vulpillières F³ ¹NEOS Health, Binningen, Switzerland, ²F. Hoffmann-La Roche, Basel, Switzerland, ³F. Hoffmann-La Roche AG, Basel, Switzerland

PCN70	COST EFFECTIVENESS ANALYSIS OF SUNITINIB, BEVACIZUMAB + INTERFERON-ALFA AND TEMSIROLIMUS AS FIRST-LINE THERAPY OF METASTATIC RENAL CELL CARCINOMA IN SWEDEN
	Remák E¹, Vioix H¹, Sandin R², Harmenberg U³, Ullén A³, Sandström P³ ¹United BioSource Corporation, London, UK, ²Pfizer AB, Sollentuna, Sweden, ³Karolinska University Hospital, Stockholm, Sweden

PCN71	COST-EFFECTIVENESS OF RITUXIMAB COMBINED WITH FLUDARABINE AND CYCLOPHOSPHAMIDE IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN FRANCE
	Roussel M¹, Troussard X², Delmer A³, Poinso M⁴, Miadi-Fargier H⁵ ¹ROCHE, Neuilly sur Seine Cedex, France, ²Clemenceau University Hospital, Caen Cedex 9, France, ³Robert Debré University Hospital, Reims Cedex, France, ⁴IMS Health, Puteaux Cedex, France, ⁵IMS Health, Puteaux, France

PCN72	EPIDEMIOLOGICAL AND COST-EFFECTIVENESS ANALYSIS OF THE CROSS PROTECTION DIFFERENCE BETWEEN THE BIVALENT AND THE QUADRIVALENT HPV VACCINES IN FRANCE
	Tehard B¹, Demarteau N², Faÿ S¹, Essoh A¹, Standaert B² ¹GlaxoSmithKline, Marly-le-Roi, France, ²GlaxoSmithKline Biologicals, Rixensart, Belgium

PCN73	COST-EFFECTIVENESS OF ADDING ZOLEDRONIC ACID TO ENDOCRINE THERAPY IN PREMENOPAUSAL WOMEN WITH HORMONE-RESPONSIVE EARLY BREAST CANCER IN GREECE, BASED ON THE ABCSG-12 STUDY
	Delea TE¹, Taneja C¹, Kaura S², Chatzikou M³, Maiadiakis N⁴, Fagoulakis V⁴ ¹PAI (Policy Analysis Inc.), Brookline, MA, USA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, ³Novartis (Hellas) S.A.C.I., Athens, Greece, ⁴National School of Public Health, Athens, Greece

PCN74	COMPARISON OF THE COST-EFFECTIVENESS OF ZOLEDRONIC ACID THERAPY FOR RENAL CELL CARCINOMA (RCC) PATIENTS WITH BONE METASTASES IN FRENCH, GERMAN, AND THE UK POPULATIONS
	Botteman MF¹, Kaura S² ¹PharMerit North America LLC, Bethesda, MD, USA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PCN75	COST-EFFECTIVENESS OF THALIDOMIDE COMBINED WITH MELPHALAN AND PREDNISONE IN PREVIOUSLY UNTREATED MULTIPLE MYELOMA IN WALES
	Joseph I¹, Facon T², Lewis P³, Deniz HB¹, Caro JJ¹ ¹United BioSource Corporation, Lexington, MA, USA, ²Centre Hospitalier Universitaire (CHU), Lille, France, ³Celgene GmbH, München , Germany

PCN76	COST-EFFECTIVENESS OF CHEMOPREVENTION WITH DUTASTERIDE BASED ON RESULTS FROM THE REDUCE CLINICAL TRIAL
	Earnshaw SR¹, McDade CL¹, Black L², Kattan MW³ ¹RTI Health Solutions, Research Triangle Park, NC, USA, ²GlaxoSmithKline, Research Triangle Park, NC, USA, ³Cleveland Clinic Foundation, Cleveland, OH, USA

PCN77	COST-EFFECTIVENESS ANALYSIS OF TEMSIROLIMUS VS. SUNITINIB MALATE IN POOR PROGNOSIS METASTATIC RENAL CELL CARCINOMA (MRCC) IN PORTUGAL
	Silverio NM¹, Yang S², Alemao E³ ¹Wyeth Portugal, Miraflores, Portugal, ²Wyeth Pharmaceuticals, Inc, Collegeville, PA, USA, ³Wyeth Research, Collegeville, PA, USA

PCN78	COST-EFFECTIVENESS ASSESSMENT OF ZOLEDRONIC ACID (ZOL) RELATIVE TO PLACEBO (PBO) IN THE TREATMENT OF LUNG CANCER PATIENTS WITH SKELETAL METASTASES IN FIVE EUROPEAN COUNTRIES
	Botteman MF¹, Logman JFS², Kaura S³ ¹PharMerit North America LLC, Bethesda, MD, USA, ²Pharmerit Europe, Rotterdam, The Netherlands, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PCN79	COST-EFFECTIVENESS EVALUATION OF THE USE OF CAPECITABINE+DOCETAXEL VS GEMCITABINE+DOCETAXEL IN PATIENTS WITH RECURRENT BREAST CANCER WHO PREVIOUSLY FAILED TO ANTHRACYCLINE CHEMOTHERAPY AND/OR WITH METASTATIC DISEASE
	Tenorio C¹, Vargas J², Martínez J³ ¹Instituto Nacional de Cancerología, Mexico, DF, Mexico, ²Econopharma Consulting SA de CV, Mexico, DF, Mexico, ³Econopharma, México D.F., Mexico

PCN80	THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN SWEDEN: RESULTS FROM A COST-EFFECTIVENESS ANALYSIS
	Nuijten MJ¹, Holmberg C², Walzer S³ ¹Ars Accessus Medica/Erasmus University Rotterdam, Amsterdam, The Netherlands, ²Roche AB, Stockholm, Sweden, ³F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland

PCN81	COST EFFECTIVENESS ANALYSIS OF BORTEZOMIB IN PREVIOUSLY UNTREATED MULTIPLE MYELOMA PATIENTS IN CANADA
	Yoong K¹, Attard C², Jivraj F¹, Shustik C³, Reece D⁴ ¹Janssen-Ortho Inc., Toronto, ON, Canada, ²Cornerstone Research Group Inc, Burlington, ON, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴Princess Margaret Hospital, Toronto, ON, Canada

PCN82	COST-EFFECTIVENESS ANALYSIS OF HPV VACCINATION IN SLOVENIA
	Obradovic M¹, Mrhar A², Kos M¹ ¹University of Ljubljana - Faculty of Pharmacy, Ljubljana, Slovenia, ²University of Ljubljana - Faculty of Pharmacy, Ljubljana, SC, Slovenia

PCN83	COST-EFFECTIVENESS ANALYSIS OF HISTAMINE DIHYDROCHLORIDE + LOW DOSE INTERLEUKIN-2 VS STANDARD OF CARE FOR ACUTE MYELOID LEUKEMIA PATIENTS IN THEIR FIRST COMPLETE REMISSION: A UK PERSPECTIVE
	Magar RS¹, Purdy C², Hayward A², Einarson TR³, Burnett AK⁴ ¹AHRM Inc., Raleigh, NC, USA, ²AHRM Inc., Buffalo, NY, USA, ³University of Toronto, Toronto, ON, Canada, ⁴University of Wales College of Medicine, Cardiff, UK

PCN84	COST-EFFECTIVENESS ANALYSES OF DOCETAXEL VERSUS PACLITAXEL ONCE WEEKLY IN PATIENTS WITH METASTATIC BREAST CANCER PROGRESSED AFTER ANTHRACYCLINE CHEMOTHERAPY IN SPAIN
	Cortés J¹, Seguí MA², Frias C², Betegón L³, Oyagüez I⁴, Casado MA⁴ ¹Hospital Universitari Vall d'Hebrón, Barcelona, Spain, ²Corporació Sanitària Parc Taulí, Sabadell, Spain, ³Sanofi-Aventis, Madrid, Spain, ⁴Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain

PCN85	COST-EFFECTIVENESS ANALYSIS OF BORTEZOMIB IN RELAPSED MANTLE CELL LYMPHOMA PATIENTS IN CANADA
	Yoong K¹, Attard C², Jivraj F¹, Sehn L³ ¹Janssen-Ortho Inc., Toronto, ON, Canada, ²Cornerstone Research Group Inc, Burlington, ON, Canada, ³British Columbia Cancer Agency, Vancouver, BC, Canada

PCN86	THE COST-EFFECTIVENESS OF BORTEZOMIB FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA – A NORDIC COMPARISON
	Liwing J¹, Gjönnes L², Sandberg I³, Renlund M⁴, Aschan J¹, Lothgren M¹, Rickert JB⁵, Hornberger J⁶, Dhawan R⁷ ¹Janssen-Cilag AB, Sollentuna, Sweden, ²Janssen-Cilag, Lysaker, Norway, ³Janssen-Cilag AS, Birkerød, Denmark, ⁴Janssen-Cilag As, Espoo, Finland, ⁵Cedar Associates LLC, Menlo Park, CA, USA, ⁶Cedar Associates LLC and Stanford University, Menlo Park, CA, USA, ⁷Johnson & Johnson Pharmaceutical Services LLC, Raritan, NJ, USA

PCN87	A COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH PEMETREXED PLUS CISPLATIN (PC) FOR THE TREATMENT OF ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY
	Bischoff HG¹, Heigener D², Wiesner C³, Walzer S⁴ ¹Thoraxklinik Heidelberg, Heidelberg, Germany, ²Krankenhaus Grosshansdorf, Grosshansdorf, Germany, ³Roche Pharma AG, Grenzach-Wyhlen, Germany, ⁴F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland

PCN88	AN ECONOMIC EVALUATION OF RITUXIMAB VERSUS OTHER FIRST-LINE TREATMENTS FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN POLAND
	Kawalec P¹, Stawowczyk E¹, Russel-Szymczyk M², Szkultecka-Debek M², Aultman R³, Carr E⁴, Lech-Maranda E⁵, Krawcewicz A⁶, Wach M⁷, Mazur G⁸ ¹Centrum HTA, Krakow, Poland, ²Roche Polska, Warsaw, Poland, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁴F. Hoffmann - La Roche, Basel, Switzerland, ⁵Medical University of Lodz, Lodz, Poland, ⁶Institute of Hematology and Transfusion Medicine, Warsaw, Poland, ⁷Medical University of Lublin, Lublin, Poland, ⁸Medical University of Wroclaw, Wroclaw, Poland

PCN89	WITHDRAWN

PCN90	MASS SCREENING FOR COLORECTAL CANCER: ARE ALTERNATIVES TO THE GUAIAC FECAL OCCULT BLOOD TEST COST-EFFECTIVE?
	Chauvin P¹, Josselin JM¹, Hess-Miglioretti A², Grolier J¹, Heresbach D³ ¹University of Rennes I, Rennes, France, ²Maison des Sciences de l'Homme en Bretagne, Rennes, France, ³University of Rennes I and University Hospital of Rennes, Rennes, France

PCN91	LONG TERM COST-EFFECTIVENESS OF DOCETAXEL PLUS CYCLOPHOSPHAMIDE COMPARED TO DOXORUBICIN PLUS CYCLOPHOSPHAMIDE AS ADJUVANT TREATMENT FOR WOMEN WITH OPERABLE BREAST CANCER
	Jackson D¹, Lee JM², Adams J¹, Gordois A¹ ¹IMS Health, St Leonards, NSW, Australia, ²Sanofi-Aventis Australia Pty Ltd, Macquarie Park, NSW, Australia

PCN92	COST-EFECTIVENESS ANALYSIS OF DOCETAXEL VS DOCETAXEL+TRASTUZUMAB AS FIRST LINE THERAPY IN THE TREATMENT OF PATIENTS WITH METATSTASTIC BREAST CANCER HER2/NEU+
	Tenorio C¹, Vargas J², Martínez J³, Paladio Á⁴ ¹Instituto Nacional de Cancerología, Mexico, DF, Mexico, ²Econopharma Consulting SA de CV, Mexico, DF, Mexico, ³Econopharma, México D.F., Mexico, ⁴Econopharma Consulting SA de CV, Mexico City, Mexico

PCN93	HEALTH ECONOMICS OF HPV VACCINATION IN AUSTRIA – COST-EFFECTIVENESS OF VACCINATING 12 YEAR OLD GIRLS
	Kundi M Medical University of Vienna, Vienna, Austria

PCN94	ECONOMIC EVALUATION OF DOCETAXEL IN THE CONTEXT OF BREAST CANCER IN PORTUGAL
	Pinto CG¹, Moreira A², Miguel LS³, Esteves S² ¹Technical University of Lisbon, Lisboa, Portugal, ²Instituto Português de Oncologia de Lisboa Francisco Gentil - EPE, Lisboa, Portugal, ³Research Centre on the Portuguese Economy - CISEP, Lisboa, Portugal

PCN95	COST-EFFECTIVENESS OF BEVACIZUMAB COMBINATION THERAPY IN METASTATIC COLORECTAL CANCER: RESULTS OF MARKOV COHORT SIMULATION FROM A SOCIAL PERSPECTIVE IN KOREA
	Kim JH, Lee EK Sook Myung Women's University, Seoul, South Korea

PCN96	COLORECTAL CANCER SCREENING: COST-EFFECTIVENESS OF CT COLONOGRAPHY
	Sweet A¹, Muston D², Lock K², Lee DW³ ¹GE Healthcare, Buckinghamshire, UK, ²Heron Evidence Development Ltd, Luton, UK, ³GE Healthcare, Waukesha, WI, USA

PCN97	COST EFFECTIVENESS OF ERLOTINIB TREATMENT GIVEN BY A CLINICALLY BASED APPROACH AND AN EGFR/KRAS TESTING-GUIDED APPROACH ADVANCED IN NON SMALL-CELL LUNG CANCER: A PROSPECTIVE MULTICENTRIC FRENCH STUDY (ERMETIC)
	Borget I¹, Cadranel J², Pignon JP³, Danton G³, Coudert B⁴, Dansin E⁵, Friard S⁶, Daniel C⁷, Quoix E⁸, Madeleine J⁹, Madroszyk A¹⁰, Morin F¹¹, Chouaid C¹² ¹Institut de Cancérologie Gustave Roussy, Villejuif, France, ²Hospital Tenon, Paris, France, ³Institut Gustave Roussy, Villejuif, France, ⁴Centre Georges François Leclerc, Dijon, France, ⁵Oscar Lambret hospital, Lille, France, ⁶Hospital Foch, Suresnes, France, ⁷Institut Curie, Paris, France, ⁸CHU Strasbourg, Strasbourg, France, ⁹CHU Caen, Caen, France, ¹⁰Institut Paoli Calmette, Marseille, France, ¹¹IFCT, Paris, France, ¹²Hopital Saint antoine, APHP, Paris, France

PCN98	COST-EFFECTIVENESS OF PROGNOSIS-BASED STRATEGIES TO SELECT WOMEN WITH BREAST CANCER FOR ADJUVANT CHEMOTHERAPY
	Bonastre J, Koscielny S Institut Gustave Roussy, Villejuif, France

PCN99	COST-EFFECTIVENESS ANALYSIS OF IMIQUIMOD VERSUS NO TREATMENT IN PATIENTS WITH SUPERFICIAL BASAL CELL CARCINOMA AND CONTRAINDICATION TO SURGICAL INTERVENTION/CRYOTHERAPY
	Walczak J, Nogas G, Dybek-Karpiuk A, Kloc K, Labak M, Pawlik D Arcana Institute, Cracow, Poland

PCN100	COST-EFFECTIVENESS OF ANASTROZOLE AS ADJUVANT TREATMENT FOR EARLY STAGES BREAST CANCER IN POSTMENOPAUSAL WOMEN
	Rudakova AV Military Medical Academy, St-Petersburg, Russia

PCN101	COST-EFFECTIVENESS OF SHORT-ACTING OPIOIDS FOR BREAKTHROUGH PAIN IN CANCER PATIENTS - A SCOTTISH-BASED DECISION-ANALYSIS MODEL
	Vissers D¹, Stam W¹, Tolley K², Sendersky V³, Jansen JP⁴ ¹Mapi Values, Houten, The Netherlands, ²Mapi Values, Bollington, UK, ³Nycomed, Taastrup, Denmark, ⁴Mapi Values, Boston, MA, USA

PCN102	COST EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH TRASTUZUMAB FOR HER2+VE BREAST CANCER IN ITALY UTILIZING FOLLOW UP DATA
	Giuliani G¹, Ray JA², Urspruch A² ¹Roche S.p.A. Italy, Monza, Italy, ²F. Hoffmann-La Roche Ltd., Basel, Switzerland

PCN103	PHARMACOECONOMIC ANALYSIS OF THE ADDITION OF RITUXIMAB TO FLUDARABINE-CYCLOPHOSPHAMIDE REGIMEN IN THE FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA PATIENTS IN SPAIN
	Bosch F¹, Casado LF², Garcia-Marco JA³, Gilsanz F⁴, Gonzalez Diaz M⁵, Rayon C⁶, Rios Herranz E⁷, De la Serna J⁴, Urbano A⁸, Vicente Garcia V⁹, Rubio-Terres C¹⁰, Castro AJ¹¹ ¹Hospital Clinic Barcelona, Barcelona, Spain, ²Hospital Virgen de la Salud, Toledo, Spain, ³Hospital Universitario Puerta Hierro, Majadahonda, Madrid, Spain, ⁴Hospital Universitario 12 de Octubre, Madrid, Spain, ⁵Hospital Clinico Universitario Salamanca, Salamanca, Spain, ⁶Hospital Central de Asturias, Oviedo, Spain, ⁷Hospital de Valme, Seville, Spain, ⁸Hospital Universitario Virgen del Rocio, Sevilla, Spain, ⁹Hospital General Universitario Reina Sofia, Murcia, Spain, ¹⁰Health Value, Madrid, Spain, ¹¹Roche Farma, Madrid, Madrid, Spain

PCN104	COST-EFFECTIVENESS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER IN CHINA
	Chen W¹, Sheng F², Qiao N¹ ¹Fudan University, Shanghai, China, ²Shanghai Roche Pharmaceuticals Ltd, Shanghai, China

PCN105	ECONOMIC EVALUATION OF TRABECTEDIN IN THE TREATMENT OF METASTATIC SOFT-TISSUE SARCOMA (MSTS) IN THE FINNISH SETTING
	Soini EJ¹, García San Andrés B², Joensuu T³ ¹ESiOR Oy, Kuopio, Finland, ²PharmaMar, Madrid, Spain, ³International Comprehensive Cancer Centre Docrates, Helsinki, Finland

PCN106	EXPLORING THE COST-EFFECTIVENESS OF A SMOKING-CESSATION PROGRAM ENHANCED WITH INDIVIDUAL GENETIC FEEDBACK ON LUNG CANCER RISK
	Gordon LG¹, Hirst NG¹, Young RP², Brown PM³ ¹Queensland Institute of Medical Research, Brisbane, Australia, ²Auckland Hospital, Auckland, New Zealand, ³The University of Auckland, Auckland, New Zealand

PCN107	COST-EFFECTIVENESS OF HPV VACCINATION – AN OVERVIEW ON INTERNATIONAL STUDY RESULTS
	Damm O, Greiner W University of Bielefeld, Bielefeld, Germany

PCN108	PHARMAECONOMIC EVALUATION OF THE USE OF PROLONGED LIBERATION HIDROMORFONE IN THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN FOR CANCER AT AN INSTITUTIONAL LEVEL IN MEXICO
	Vargas J¹, Tenorio C², Martínez J³, Soto-Molina H⁴, Castillejos Zenteno C⁴ ¹Econopharma, Mexico, Mexico, ²Instituto Nacional de Cancerología, Mexico, DF, Mexico, ³Econopharma, México D.F., Mexico, ⁴Janssen Cilag, Mexico, Mexico

PCN109	COST-EFFECTIVENESS OF RITUXIMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN THE DUTCH SETTING
	Pompen M¹, ten Hoor G¹, Carr E², Aultman R² ¹Roche Nederland b.v., Woerden, The Netherlands, ²F. Hoffmann - La Roche, Basel, Switzerland

PCN110	COST-MINIMIZATION ANALYSIS OF XELOX VERSUS FOLFOX ± BEVACIZUMAB FOR TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) IN SAUDI ARABIAN HOSPITAL SETTING
	Zazaa AS¹, AlOmar H², El-Moursy SA³, AlFayyadh M² ¹F. Hoffmann-La Roche Ltd, Jeddah, Saudi Arabia, ²Healthcare Experts, Riyadh, Saudi Arabia, ³King AbdulAziz Hospital and Oncology Center, Jeddah, Western Province, Saudi Arabia

PCN111	COST MINIMIZATION ANALYSIS FOR STAPLED VERSUS HANDSEWN SURGERY TECHNIQUES FOR ANASTOMOSES IN SURGICAL TREATMENT FOR COLON CANCER, UNDER THE BRAZILIAN PUBLIC PAYER PERSPECTIVE
	Nasciben VD¹, Nogueira EDM¹, Carone M² ¹Johnson & Johnson Medical Brasil, São Paulo, SP, Brazil, ²Jonhson & Jonhson Medical, Mexico, DF, Mexico

PCN112	COST MINIMIZATION ANALYSIS FOR STAPLED VERSUS HANDSEWN SURGERY TECHNIQUES FOR ANASTOMOSES IN SURGICAL TREATMENT FOR COLON CANCER, UNDER BRAZILIAN PRIVATE PAYER PERSPECTIVE
	Nasciben VD¹, Nogueira EDM¹, Carone M² ¹Johnson & Johnson Medical Brasil, São Paulo, SP, Brazil, ²Jonhson & Jonhson Medical, Mexico, DF, Mexico

PCN113	PHARMACOECONOMIC ANALYSIS OF CAPECITABINE PLUS OXALIPLATIN (XELOX) VERSUS 5-FLUOROURACIL/LEUCOVORIN PLUS OXALIPLATIN (FOLFOX) IN THE FIRST LINE TREATMENT OF METASTASIS COLORECTAL CANCER IN TAIWAN
	Chen HH¹, Chang CS², Chen LT³, Chen WT⁴, Hsu TC⁵, Wang JY⁶, Wen CY⁷ ¹Chang Guang Memorial Hospital, Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan, ²Changhua Christian Memorial Hospital, Changhua, Taiwan, ³National Health Research Institutes, Taipei, Taiwan, ⁴China Medical University, School of Medicine, Taichung, Taiwan, ⁵Taipei Medical University, Taipei, Taiwan, ⁶Kaoshiung Medical University Hospital, Kaohsiung, Taiwan, ⁷Roche Products Ltd., Taipei, Taiwan

PCN114	COST-EFFECTIVENESS ANALYSIS OF PEMETREXED/CISPLATIN IN THE FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN ITALY: RESULTS FOR THE ADENOCARCINOMA HISTOLOGY SUB-POPULATION
	Guidi L¹, Malik S², Valle D¹, Asukai Y², Taipale K³ ¹Eli Lilly Italia S.p.A., Firenze, Italy, ²IMS Health, London, UK, ³Eli Lilly and Company, Lilly Research Centre, Windlesham, UK

PCN115	COST UTILITY ANALYSIS OF 90Y-IBRITUMOMAB TIUXETAN FOLLOWING FIRST-LINE CHEMOTHERAPY COMPARED TO NO FOLLOW-UP IN PATIENTS WITH STAGE III OR IV FOLLICULAR LYMPHOMA IN SPAIN
	Eggington S¹, Piñol C², Musi E³, Valderrama A⁴ ¹IMS Health, London, Camden, UK, ²Bayer HealthCare, Barcelona, Spain, ³Bayer HealthCare, Sant Joan Despí (Barcelona), Catalonia, Spain, ⁴Bayer Healthcare Pharmaceuticals Inc, Pine Brook, NJ, USA

PCN116	A SURVIVAL BASED COST-EFFECTIVENESS ANALYSIS OF 5 YEARS LETROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER: CANADIAN PERSPECTIVE
	El Ouagari K¹, Kaura S², Karnon JD³ ¹Novartis Pharmaceuticals, Dorval, QC, Canada, ²Novartis Pharmaceuticals, East Hanover, NJ, USA, ³University of Adelaide, Adelaide, Australia

PCN117	COST-UTILITY MODEL TO EVALUATE ADJUVANT CHEMOTHERAPY FOR EARLY BREAST CANCER IN THE USA
	Wolowacz SE¹, Jhaveri M², Tangirala M³ ¹RTI-Health Solutions, Manchester, UK, ²sanofi-aventis USA, Bridgewater, NJ, USA, ³Smith Hanley Consulting Group LLC, Lake Mary, FL, USA

PCN118	COST EFFECTIVENESS OF CETUXIMAB IN FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER: DESCRIPTION OF A NICE SUBMISSION
	Eggington SG¹, Garrell D², Griebsch I³, Samyshkin Y¹ ¹IMS Health, London, UK, ²Merck Serono UK, Feltham, UK, ³Merck KGaA, Darmstadt, Germany

PCN119	COST EFFECTIVENESS ANALYSIS OF ANASTROZOLE VERSUS TAMOXIFEN IN ADJUVANT THERAPY FOR EARLY STAGE BREAST CANCER BASED ON THE 100-MONTH ANALYSIS OF THE ATAC TRIAL FROM A GERMAN PERSPECTIVE
	Kreif N¹, Benedict Á², Lux MP³, Wöckel A⁴, Klevesath MB⁵ ¹United BioSource--Europe, London, UK, ²United BioSource Corporation, Budapest, Hungary, ³University of Erlangen, Erlangen, Germany, ⁴University of Ulm, Ulm , Germany, ⁵AstraZeneca GmbH, Wedel, GA, Germany

PCN120	COST-UTILITY OF DOCETAXEL COMPARED WITH BEST SUPPORTIVE CARE AND PEMETREXED IN SECOND LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN POLAND
	Rutkowski J¹, Gwiosda B¹, Lisiecka B¹, Wladysiuk M¹, Lis J², Plisko R¹, Rys P¹ ¹HTA Consulting, Krakow, Poland, ²Sanofi-Aventis, Warsaw, Poland

PCN121	COST-EFFECTIVENESS OF A POPULATION-BASED COLORECTAL CANCER SCREENING PROGRAMME IN IRELAND
	Sharp L¹, Tilson L², Whyte S³, O'Ceilleachair A¹, Walsh C⁴, Usher C², Tappenden P³, Chilcott J³, Staines A⁵, Comber H¹, Barry M² ¹National Cancer Registry of Ireland, Cork, Ireland, ²National Centre for Pharmacoeconomics, Dublin, Ireland, ³School for Health and Related Research (ScHARR), Sheffield, UK, ⁴Trinity College Dublin, Dublin, Ireland, ⁵Dublin City University, Dublin, Ireland

PCN122	COST-EFFECTIVENESS ANALYSIS OF HORMONAL THERAPIES IN PATIENTS WITH ADVANCED PROSTATE CANCER IN ITALY
	Iannazzo S¹, Pradelli L¹, Perachino M² ¹AdRes HE&OR, Torino, Italy, ²Ospedale S. Spirito, Casale Monferrato (AL), Italy

PCN123	LONG-TERM COST-EFFECTIVENESS OF ANASTROZOLE VERSUS TAMOXIFEN – AN UPDATED ANALYSIS BASED UPON THE 100 MONTH FOLLOW UP OF THE ANASTROZOLE OR TAMOXIFEN ALONE OR IN COMBINATION (ATAC) TRIAL
	Paulsson T¹, Jönsson PE², Brattström D³ ¹Dept of Health Economics, Södertälje, Sweden, ²Department of Surgery, Helsingborg, Sweden, ³Medical Affairs, Södertälje, Sweden

PCN124	COST-UTILITY ANALYSIS OF DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) ON CHRONIC (CP), ACCELERATED (AP) AND BLAST (BP) PHASES IN BRAZIL
	Asano E¹, Nita M¹, Moellmann-Coelho A², Rached R¹, Donato B³, Rahal E¹ ¹Bristol-Myers Squibb S/A, São Paulo, São Paulo, Brazil, ²Instituto Nacional de Cancer (INCA), Rio de janeiro, Rio de Janeiro, Brazil, ³Bristol-Myers Squibb, Wallingford, CT, USA

PCN125	AN ECONOMICAL, RANDOMIZED, MULTICENTER PHASE III TRIAL OF SECOND LINE TREATMENT FOR NON SMALL CELL LUNG CANCER (NSCLC) COMPARING DOCETAXEL VERSUS PEMETREXED: GFPC (GROUPE FRANçAIS DE PNEUMO-CANCéROLOGIE) 05-06 STUDY
	Vergnenegre A¹, Corre R², Berard H³, Paillotin D⁴, Dujon C⁵, Robinet G⁶, Crequit J⁷, Bota S⁸, Thomas P⁹, Chouaid C¹⁰ ¹CHU Limoges, Limoges, France, ²CHU Pontchailloux, Rennes, France, ³Hôpital d'Instruction des Armées Sainte-Anne, Toulon Naval, France, ⁴CHU de Rouen, Rouen, France, ⁵Hôpital A. Mignot, Le Chesnay, France, ⁶Oncologie Thoracique, Brest, France, ⁷Service de Pneumologie, Beauvais, France, ⁸Clinique Pneumologique, Rouen, France, ⁹Centre Hospitalier Intercommunal des Alpes du Sud, GAP, France, ¹⁰Hopital Saint antoine, APHP, Paris, France

PCN126	LOSS OF WORK ACTIVITY AND PRODUCTIVITY IN CAREGIVERS ATTENDING TO PATIENTS WITH ADVANCED RENAL CELL CARCINOMA TREATED WITH TEMSIROLIMUS OR INTERFERON-ALFA: EVALUATIONS FROM A PHASE 3 RANDOMIZED TRAIL
	Yang S¹, Alemao E² ¹Wyeth Pharmaceuticals, Inc, Collegeville, PA, USA, ²Wyeth Research, Collegeville, PA, USA

PCN127	DYNAMIC CONTRAST-ENHANCED ULTRASOUND WITH QUANTIFICATION TO ASSESS TARGETED TREATMENT EFFICACY: RESULTS OF A MULTI-CENTRIC PROSPECTIVE COST STUDY
	Bonastre J, Chevalier J, Koscielny S, Lassau N Institut Gustave Roussy, Villejuif, France

PCN128	BREAST CANCER DIAGNOSTIC PROCESS: MANAGEMENT AND COST EVALUATION IN ITALY
	Pantaleoni M, Marchese E IMS Health S.p.A., Milano, Italy

PCN129	FACTORS AFFECTING ADMINISTRATION REGIMES AND COSTS ASSOCIATED WITH EIGHT FIRST-LINE CHEMOTHERAPEUTIC DRUGS IN SEVEN COMBINATIONS, IN THE TREATMENT OF MNSCLC
	Rosery H¹, Rautenberg T¹, Walzer S² ¹AiM GmbH Assessment-in-Medicine, Schopfheim, Germany, ²F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland


CANCER Patient-Reported Outcomes Studies
PCN130	HEALTH UTILITIES OF CHILDREN TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN DFCI 95-01 RANDOMIZED CLINICAL TRIAL
	Furlong W¹, Barr RD¹, Rae CS¹, Feeny DH², Sallan S³ ¹McMaster University, Hamilton, ON, Canada, ²Kaiser Permanente Center for Health Research, Portland, OR, USA, ³Harvard University, Boston, MA, USA

PCN131	WITHDRAWN

PCN132	UTILITY LIBRARY TO CAPTURE UTILITIES IN THE AREA OF ONCOLOGY
	Stafford MR¹, Van Hanswijck de Jonge P¹, Manson SC¹, Walker M² ¹United BioSource Corporation, London, UK, ²GlaxoSmithKline, London, UK

PCN133	POPULATION PREFERENCES FOR TREATMENT OUTCOMES IN CHRONIC LYMPHOCYTIC LEUKEMIA
	Davies J¹, Leach M², Meiklejohn D³, Grinspan J⁴, Bramham-Jones S⁵, O'Toole A⁶, Beusterien K⁷ ¹Western General Hospital, Edinburgh, UK, ²Leukaemia Research Lab, Glasgow, UK, ³NHS Tayside, Dundee, UK, ⁴Oxford Outcomes, Bethesda, MD, USA, ⁵Napp Pharmaceuticals Limited, Cambridge , UK, ⁶Napp Pharmaceuticals Limited, Cambridge, UK, ⁷Oxford Outcomes Inc, Bethesda, MD, USA

PCN134	VALIDATION OF A KOREAN TRANSLATION OF CANCER THERAPY SATISFACTION QUESTIONNAIRE (CTSQ): A PILOT STUDY
	An SM, Kim S, Choi WC, Eo WK, Chung HS, Kim KS, Yoon SW, Eom SK, Cheon SH, Lee SH Kyung Hee University, Seoul, South Korea

PCN135	USING THE FACT-LEUKEMIA SUBSCALE TO EVALUATE QUALITY OF LIFE IN LEUKEMIA PATIENTS WORLDWIDE
	Arnold BJ¹, Debb S¹, Bruce J¹, Bredle J¹, Cella D² ¹FACIT.org, Elmhurst, IL, USA, ²Northwestern University, Chicago, IL, USA

PCN136	COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) USE AMONG LOCAL STAGE PROSTATE CANCER PATIENTS: TYPES, FACTORS ASSOCIATED WITH USE AND PERCEIVED BENEFITS
	Ramsey SD¹, McDermott CL¹, Zeliadt SB², Blough DK³, Fedorenko CR¹, Arora NK⁴, Penson DF⁵, Oakley-Girvan I⁶, Hamilton AS⁷, Van Den Eeden SK⁸, Potosky AL⁹ ¹Fred Hutchinson Cancer Research Center, Seattle, WA, USA, ²VA Puget Sound Health Care System, Seattle, WA, USA, ³University of Washington, Seattle, WA, USA, ⁴National Cancer Institute, Bethesda, MD, USA, ⁵University of Southern California / Norris Cancer Center, Los Angeles, CA, USA, ⁶Northern California Cancer Center, Fremont, CA, USA, ⁷USC/Norris Comprehensive Cancer Center, Los Angeles, CA, USA, ⁸Kaiser Permanente, Oakland, CA, USA, ⁹Georgetown University Medical Center, Washington, DC, USA

PCN137	ONCOLOGY PATIENT-REPORTED CLAIMS: MAXIMISING THE CHANCE FOR SUCCESS
	Rofail D¹, Abetz L¹, Caron M², Emery MP², Kitchen H¹ ¹Mapi Values Ltd, Bollington, Cheshire, UK, ²Mapi Research Trust, Lyon, France

PCN138	INFORMATION NEEDS: A STUDY ABOUT ONCOLOGICAL PATIENTS IN THE ITALIAN CONTEXT
	Passalacqua S, Mozzetta A, Di Pietro C, Marchetti P, Tabolli S IDI IRCCS, Rome, Italy

PCN139	FINAL QUALITY OF LIFE (QOL) RESULTS WITH GEOGRAPHICAL ANALYSIS FOR SUNITINIB VERSUS INTERFERON-ALFA, AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
	Cella D¹, Michaelson MD², Bushmakin AG³, Cappelleri JC³, Charbonneau C⁴, Kim ST⁵, Li JZ⁵, Motzer RJ⁶ ¹Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA, ²Massachusetts General Hospital Cancer Center, Boston, MA, USA, ³Pfizer Oncology, New London, CT, USA, ⁴Pfizer Oncology, New York, NY, USA, ⁵Pfizer Oncology, La Jolla, CA, USA, ⁶Memorial Sloan-Kettering Cancer Center, New York, NY, USA

PCN140	IMPACT OF TUMOR RESPONSE ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH VELCADE/MELPHALAN/PREDNISONE (V-MP): RESULTS FROM THE VISTA TRIAL
	Meunier J¹, Regnault A², Robinson D³, Rosa K⁴, San Miguel JF⁵, van de Velde H⁶, Richardson PG⁷, Cakana A⁶, Dhawan R⁸ ¹Mapi Values, Lyon, France, ²Mapi Values France, Lyon, France, ³Johnson & Johnson Pharmaceutical Services, Malvern, PA, USA, ⁴Mapi Values, Boston, MA, USA, ⁵Hospital Universitario Salamanca, Salamanca, Spain, ⁶Johnson & Johnson Pharmaceutical R&D, Beerse, Belgium, ⁷Dana-Farber Cancer Institute, Boston, MA, USA, ⁸Johnson & Johnson Pharmaceutical Services LLC, Raritan, NJ, USA

PCN141	QUALITY OF LIFE (QOL) IN PATIENTS WITH METASTATIC BREAST CANCER (MBC) FROM THE AVADO STUDY: THE IMPORTANCE OF IMPUTATION METHODS FOR HANDLING MISSING DATA
	Greil R¹, Miles D², Siebert U³ ¹Medical University of Salzburg, Salzburg, Austria, ²Mount Vernon Cancer Centre, London, UK, ³University for Health Sciences, Medical Informatics and Technology/Oncotyrol, Hall i.T, Austria

PCN142	EVALUATION OF THE QUALITY OF LIFE IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WHO FAILED TO FIRST LINE CHEMOTHERAPY IN TREATMENT WITH ERLOTINIB VS TAXANES
	Vargas J¹, Gomez Rangel JD², Martínez-Barrera L³, Mendoza D³, Paladio Á⁴ ¹Econopharma Consulting SA de CV, Mexico, DF, Mexico, ²Centro Médico Nacional Siglo XXI. Hospital de Oncología, Mexico, Mexico, ³Instituto Nacional de Enfermedades Respiratorias, Mexico, Mexico, ⁴Econopharma Consulting SA de CV, Mexico City, Mexico

PCN143	WILLINGNESS TO PAY FOR A LIFE-YEAR GAINED FROM THE PERSPECTIVE OF THE GENERAL POPULATION
	Obradovic M, Mrhar A, Kos M University of Ljubljana - Faculty of Pharmacy, Ljubljana, Slovenia

PCN144	WITHDRAWN

CANCERHealth Care Use & Policy Studies
PCN145	HEALTH ECONOMIC REVIEW OF NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENT IN THE UNITED STATES
	Munakata J¹, Trochlil K¹, Battleman DS¹, Foley D² ¹IMS Health, Falls Church, VA, USA, ²Boehringer Ingelheim Ltd, Ridgefield, CT, USA

PCN146	MIND THE GAP: ASSESSING THE DIFFERENT DATA REQUIREMENTS BETWEEN REGULATORY APPROVAL AND HEALTH TECHNOLOGY ASSESSMENT
	Ng-Haing J¹, Long M², Sparrowhawk K² ¹Lon don School of Economics, International Health Policy MSc, London, UK, ²PriceSpective, London, UK

PCN147	FIELD TESTING OF A MULTICRITERIA DECISION ANALYSES (MCDA) FRAMEWORK FOR COVERAGE OF A DIAGNOSTIC TEST FOR CERVICAL CANCER IN SOUTH AFRICA
	Miot J¹, Wagner M², Khoury H², Anderson AN³, Rindress D², Goetghebeur MM² ¹University of Pretoria, Pretoria, Gauteng, South Africa, ²BioMedCom Consultants Inc, Montreal, QC, Canada, ³Discovery Health, Sandton, Johannesburg, South Africa

PCN148	ADDRESSING DECISIONS ABOUT CLINICAL GUIDANCE AND ITS ACTIVE IMPLEMENTATION: SEQUENTIAL OR INTEGRAL ANALYSIS? AN APPLICATION IN METASTATIC HORMONE-REFRACTORY PROSTATE CANCER
	Hoomans T¹, Severens JL², Ament AJHA¹, Fenwick E³ ¹Maastricht University, Maastricht, The Netherlands, ²University Hospital Maastricht, Maastricht, The Netherlands, ³University of Glasgow, Glasgow, UK

PCN149	COST ANALYSIS OF 10-YEARS FOLLOW-UP OF CHEMOTHERAPY REGIMENS WITHIN THE SLOVAK REPUBLIC
	Tesar T, Foltan V, Binder R Comenius University, Bratislava, Slovak Republic

PCN150	THE RELATIONSHIP BETWEEN DRUG UTILIZATION AND OUT OF POCKET EXPENSES FOR ORAL ANTINEOPLASTICS COMPARED TO A MARKET BASKET OF COMMONLY USED DRUGS
	Sepulveda B, Doyle JJ, White C Quintiles Consulting, Hawthorne, NY, USA

PCN151	CROSS-REGIONAL FLOWS OF CANCER PATIENTS IN GREECE: URBANIZATION OF CANCER TREATMENT
	Athanasakis K¹, Souliotis K², Kyriopoulos J¹ ¹National School of Public Health, Athens, Greece, ²University of Peloponnese, Maroussi, Greece

PCN152	NEW JAPANESE PREFECTURAL GOVERNMENT CANCER CONTROL PROGRAMS: A SYSTEMATIC REVIEW AND AN INTERNATIONAL COMPARISON
	Imai H¹, Nakao H¹, Sata F¹, Fukuda Y² ¹National Institute of Public Health, Wako-shi, Saitama, Japan, ²Yamaguchi University, Ube, Yamaguchi, Japan

PCN153	PERFORMANCE MONITORING OF ORGANIZED CANCER SCREENING PROGRAMMES USING ADMINISTRATIVE DATA
	Majek O¹, Dusek L¹, Andres P¹, Danes J², Zavoral M³, Dvorak V⁴, Kozeny P⁵ ¹Masaryk University, Brno, Czech Republic, ²Charles University, 1st Faculty of Medicine, General University Hospital, Prague, Czech Republic, ³Charles University, 1st Faculty of Medicine, Central Military Hospital, Prague, Czech Republic, ⁴Czech Gynecological and Obstetrical Society, Brno, Czech Republic, ⁵National Reference Centre, Prague, Czech Republic

PCN154	ANTICANCER DRUG EXPENDITURE IN CATALONIA 2003-2007
	Paladio Duran N¹, Almazán Sáez C¹, Prat Casanovas A² ¹Catalan Agency of Health Technology Assessment and Research, Barcelona, Spain, ²Department of Health. Catalan Government, Barcelona, Spain

PCN155	“PATIENT ACCESS SCHEMES” – THE USE OF RISK-SHARING IN THE UK
	Carroll SM¹, Wasiak R² ¹United BioSource Corporation (UBC), London, London, UK, ²United BioSource--Europe, London, UK

PCN156	EFFECTS OF PHARMACEUTICAL INNOVATION AND DEMOGRAPHIC CHANGE ON THE GERMAN ONCOLOGY MARKET
	Ilgin Y IMS Health, Frankfurt, Germany

PCN157	COST-EFFECTIVENESS OF UGT1A1 GENOTYPING IN IRINOTECAN CANCER THERAPY
	Obradovic M¹, Mrhar A², Kos M¹ ¹University of Ljubljana - Faculty of Pharmacy, Ljubljana, Slovenia, ²University of Ljubljana - Faculty of Pharmacy, Ljubljana, SC, Slovenia

PCN158	LUXEMBOURG LUNG CANCER PROJECT: POTENTIAL CLINICAL AND ECONOMIC IMPACT OF BIOMARKER DEVELOPMENT IN THE DIAGNOSIS AND TREATMENT OF SINGLE PULMONARY NODULES IN LUXEMBOURG
	Carlson JJ¹, Clarke L², Berchem G³, Schlesser M³, Nelson J⁴, Ramsey SD⁴ ¹University of Washington, Seattle, WA, USA, ²Cornerstone Systems Northwest, Inc, Lynden, WA, USA, ³Centre Hospitalier de Luxembourg, Luxembourg City, Luxembourg, ⁴Fred Hutchinson Cancer Research Center, Seattle, WA, USA

PCN159	TREND OF METASTASECTOMY AND CHEMO- AND BIOLOGIC THERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER
	Wang F(¹, Song X², Zhao Z³, Barber B³, Long SR⁴ ¹Amgen Inc, Thousand Oaks, CA, USA, ²Thomson Reuters, Cambridge, MA, USA, ³Amgen, Inc., Thousand Oaks, CA, USA, ⁴Thomson Reuters, Hampden, ME, USA

PCN160	MODELLING NUMBER OF CANCER PATIENTS POTENTIALLY TREATED WITH TARGETED PHARMACOTHERAPY IN THE CZECH REPUBLIC
	Pavlik T¹, Dusek L¹, Majek O¹, Koptikova J¹, Vyzula R², Finek J³ ¹Masaryk University, Brno, Czech Republic, ²Masaryk Memorial Cancer Institute, Brno, Czech Republic, ³University Hospital, Pilsen, Czech Republic

PCN161	REIMBURSEMENT OF ADMINISTRATION COSTS ARE UNAFFECTED BY SINGLE, DOUBLE OR TRIPLE ANTI-CANCER THERAPY COMBINATIONS IN THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) IN FRANCE AND GERMANY
	Rosery H¹, Bischoff HG², Vergnenegre A³, Chouaid C⁴, Walzer S⁵ ¹AiM GmbH Assessment-in-Medicine, Schopfheim, Germany, ²Thoraxklinik Heidelberg, Heidelberg, Germany, ³University Hospital, Limoges, France, ⁴Hôpital Saint-Antoine, Paris, France, ⁵F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland

PCN162	REIMBURSEMENT OF ACTIVE-IMMUNOTHERAPEUTICS (AI): AN ANALYSIS BASED ON A STUDY OF CURENT REIMBURSEMENT APPROACHES
	de Cambra S¹, Mladsi D², Neale S³, Faulkner EC² ¹RTI Health Solutions, Barcelona, Spain, ²RTI Health Solutions, Research Triangle Park, NC, USA, ³RTI-Health Solutions, Otawa, Ontario, Canada

PCN163	RURAL-URBAN DIFFERENCES IN COLORECTAL CANCER HOSPITALIZATIONS IN WEST VIRGINIA, USA
	Shah N West Virginia University, Morgantown, WV, USA

PCN164	TWO DIFFERENT DOSES OF PALONOSETRON (PAL) FOR PREVENTION OF CHEMOTHERAPY-INDUCED VOMITING (CIV) IN PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC (MOHE) TREATMENT: SYSTEMATIC REVIEW (SR) AND META-ANALYSIS (MA)
	Engel T¹, Clark O¹, Paladini L¹, Faleiros E¹, Clark LG², Pegoretti B¹ ¹Evidencias Medicas, Campinas, SP, Brazil, ²Evidencias Medicas, Campinas, sp, Brazil

PCN165	SYSTEMATIC REVIEW OF PUBLISHED META-ANALYSES, SYSTEMATIC REVIEWS, AND HEALTH TECHNOLOGY ASSESSMENTS OF RITUXIMAB FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA
	Santos EA, Minowa E Roche Brazil, Sao Paulo, SP, Brazil

PCN166	TRAZTUZUMAB ON ADJUVANT BREAST CANCER TREATMENT: EVIDENCE SYNTHESIS AND A HEALTH TECHNOLOGY EVALUATION
	Clark O¹, Paladini L¹, Clark LG², Pegoretti B¹, Faleiros E¹, Engel T¹ ¹Evidencias Medicas, Campinas, SP, Brazil, ²Evidencias Medicas, Campinas, sp, Brazil

PCN167	REVIEW OF THE DECISIONS OF HEALTH TECHNOLOGY ASSESSMENT AGENCIES FOR CAPECITABINE FOR THE TREATMENT OF COLORECTAL CANCER
	Saggia MG, Borges LG Roche Brazil, Sao Paulo, SP, Brazil

PCN168	WITHDRAWN

PCN169	REVIEW OF THE DECISIONS OF HEALTH TECHNOLOGY ASSESSMENT AGENCIES FOR CAPECITABINE FOR THE TREATMENT OF BREAST CANCER
	Saggia MG, Borges LG Roche Brazil, Sao Paulo, SP, Brazil

PCN170	PUBLIC REGULATION OF THE CANCER DRUGS MARKET IN FRENCH HOSPITALS
	Degrassat-Théas A¹, Bensadon M², Rieu C¹, Le Pen C³, Paubel P¹ ¹Sainte-Anne Hospital, Paris, France, ²Agence Technique de l'Information sur l'Hospitalisation, Lyon, France, ³Dauphine University, Paris, France

PCN171	IDENTIFYING STRUCTURAL UNCERTAINTY IN ECONOMIC MODELS OF CANCER TREATMENTS: A CASE STUDY OF IRINOTECAN IN COLORECTAL CANCER (CRC)
	Shabaruddin FH¹, Elliott RA², Valle JW³, Saunders MP³, Newman WG¹, Payne K¹ ¹The University of Manchester, Manchester, UK, ²University of Nottingham, Nottingham, UK, ³The Christie NHS Foundation Trust, Manchester, UK

PCN172	TREATMENT PATTERNS AMONG PATIENTS WITH ADVANCED BREAST CANCER PREVIOUSLY TREATED WITH AN ANTHRACYCLINE AND A TAXANE: A RETROSPECTIVE LONGITUDINAL STUDY
	Colman S¹, Strizek A¹, O'Leary BA¹, Ruth AJ², Cook GA² ¹Covance Pty Ltd, Sydney, Australia, ²Bristol-Myers Squibb Pharmaceuticals, Melbourne, Australia

POSTER PRESENTATIONS SESSION I
SET-UP:	Sunday, 25 October, 11:30 – 12:00
POSTER DISPLAY HOURS:	Sunday, 25 October, 12:00 – 19:30
POSTER AUTHOR DISCUSSION HOUR:	Sunday, 25 October, 17:30 – 18:30
DISMANTLE:	Sunday, 25 October, 19:30 – 20:00

INDIVIDUAL'S HEALTH Clinical Outcomes Studies
PIH1	PERCEPTION OF PAIN AFTER CAESAREAN SECTION FROM THE POINT OF VIEW OF PUERPERAL MOTHERS
	Kovács E, Vránics I, Boncz I, Paljunite A, Bódis J, Gabara K, Kriszbacher I University of Pécs, Pécs, Hungary

PIH2	ADVERSE EVENTS ASSOCIATED WITH THE USE OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRI'S) ANTIDEPRESSANT MEDICATIONS AMONG CHILDREN: A REVIEW OF THE FDA ADVERSE EVENT REPORTING SYSTEM (AERS)
	Chen H University of Houston, Houston, TX, USA

PIH3	DUTASTERIDE PLUS TAMSULOSIN PROVIDES SUPERIOR IMPROVEMENTS IN PATIENT-REPORTED QUALITY OF LIFE: 4-YEAR RESULTS FROM THE COMBINATION OF AVODART® AND TAMSULOSIN (COMBAT) STUDY
	Haillot O¹, Budia A², Wilson T³, Black L³ ¹Universite F. Rabelais, Tours, France, ²La Fe University Hospital, Valencia, Spain, ³GlaxoSmithKline, Research Triangle Park, NC, USA

PIH4	ROLE OF LIFESTYLE-RELATED FACTORS IN PELVIC FLOOR MUSCLE STRENGTH CHANGES DURING PREGNANCY
	Hock M, Kránicz J, Kriszbacher I, Boncz I, Bódis J University of Pécs, Pécs, Hungary

PIH5	EXAMINATION OF GAIT DURING THE TRIMESTERS OF PREGNANCY
	Hock M, Dálnoki É, Dakos Z, Kriszbacher I, Boncz I, Kránicz J, Bódis J University of Pécs, Pécs, Hungary

PIH6	CHANGES OF HEART RATE VARIABILITY AFTER SHORT-TERM MEDITATION TRAINING IN COLLEGE STUDENT
	Chung JH, Kim SH Catholic University, Seoul, South Korea

PIH7	MORTALITY ACCORDING TO THE DAY OF ADMISSION IN INTENSIVE CARE UNITS AND MATERNITY WARDS IN HUNGARY
	Gresz M¹, Varga S², Kriszbacher I², Boncz I² ¹National Health Insurance Fund Administration (OEP), Budapest, Hungary, ²University of Pécs, Pécs, Hungary

INDIVIDUAL'S HEALTHCost Studies
PIH8	A BUDGET IMPACT ANALYSIS OF DIENOGEST IN TREATING ENDOMETRIOSIS ASSOCIATED PELVIC PAIN IN GERMANY
	Knight C¹, Colligs A², Lipinski J³ ¹RTI Health Solutions, Manchester, UK, ²Bayer Schering Pharma AG, Berlin, Germany, ³Bayer Vital, Leverkusen, Germany

PIH9	PREVALENCE AND BURDEN OF ILLNESS OF MENOPAUSE: A CANADIAN OBSERVATIONAL STUDY
	Iskedjian M¹, Shapiro M², Wang M³, Farah B⁴, Walker J¹ ¹PharmIdeas Research and Consulting Inc, Oakville, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Wyeth Pharmaceuticals, Markham, ON, Canada, ⁴PharmIdeas Research and Consulting Inc, Ottawa, ON, Canada

PIH10	ESTIMATING THE BURDEN OF WOMEN SUFFERING FROM PMS/PMDD: ANALYSIS OF A CROSS-SECTIONAL DATASET
	Lowin J¹, Endicott J², Patel R¹, Lindemann M³, Colligs A³, Heinemann L⁴ ¹IMS Health, London, UK, ²Columbia Univeristy College of Physicians and Surgeons, New York, NY, USA, ³Bayer Schering Pharma, Berlin, Germany, ⁴ZEG-Centre for Epidemiology & Health Research Berlin, Panketal, Germany

PIH11	SOCIO-ECONOMIC ASPECTS OF THE PRENATAL DIAGNOSIS OF CYTOMEGALOVIRUS (CMV) INFECTION IN GERMANY: A BURDEN OF DISEASE STUDY
	Walter E¹, Brennig C¹, Schöllbauer V², Halwachs-Baumann G³ ¹IPF - Institute for Pharmaeconomic Research, Vienna, Austria, ²Institute for Pharmaeconomic Research, Vienna, Austria, ³Krankenhaus Steyr, Steyr, Austria

PIH12	ECONOMIC BURDEN OF POSTMENOPAUSAL OSTEOPOROSIS IN GERMANY: A SYSTEMATIC REVIEW
	Steinle T¹, Dieudonné G² ¹Amgen GmbH, Munich, Germany, ²Kompetenz: Gesundheit, Blaustein, Germany

PIH13	COST-EFFECTIVENESS OF REDUCING MULTIPLE BIRTHS: IN-VITRO FERTILIZATION STRATEGIES IN CANADA
	Zowall H¹, Brewer C² ¹McGill University, Montreal, QC, Canada, ²Zowall Consulting, Westmount, QC, Canada

PIH14	THE COST-EFFECTIVENESS OF ETONOGESTREL/ETHINYL ESTRADIOL VAGINAL RING IN SCOTLAND
	Jensen JAG, Patel R, Mohlala BKF Schering-Plough Ltd, Welwyn Garden City, Hertfordshire, UK

PIH15	AN ECONOMIC EVALUATION OF DROSPIRENONE 2 MG / ESTRADIOL 1.033 MG VERSUS TIBOLONE 2.5MG IN THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH GRADE 1 OR 2 HYPERTENSION IN KOREA
	Jung S¹, Watson PR², Asukai Y², Jeong M¹ ¹Bayer Korea, Seoul, South Korea, ²IMS Health, London, UK

PIH16	ECONOMIC EVALUATION OF TWO ALTERNATIVE TREATMENTS FOR OVARIAN STIMULATION IN ASSISTED REPRODUCTION
	Navarro Espigares JL¹, Hernández Torres E¹, Castilla Alcalá JA¹, Padial Ortiz MA¹, Pérez Carrascosa FM² ¹University Hospital Virgen de las Nieves, Granada, Spain, ²Alhamar Labs, Granada, Spain

PIH17	ECONOMIC EVALUATION OF THE TRANSDERMAL CONTRACEPTIVE PATCH EVRA IN MEXICO: THE POPULAR HEALTH CARE SYSTEM PERSPECTIVE
	Reyes A¹, Hernandez Casas N², Lara R³, Velazquez N³, Lira J³, Delgado O⁴, Soto-Molina H⁴, Castillejos C⁴ ¹Mexican Children Hospital, Mexico City, D.F, Mexico, ²Private consulting, Mexico, Mexico, ³Instituto Nacional de Perinatologia, Mexico, Mexico, ⁴Janssen Cilag, Mexico, Mexico

PIH18	PHARMACOECONOMIC STUDY OF THE TRANSDERMAL CONTRACEPTIVE PATCH EVRA IN MEXICO: INSURANCE COMPANIES PERSPECTIVE
	Reyes A¹, Blanquet J², Hernandez Casas N³, Martinez Chequer JC⁴, Soto-Molina H⁵, Celaya JM⁵, Castillejos C⁵ ¹Mexican Children Hospital, Mexico City, D.F, Mexico, ²Private physician, Mexico, Mexico, ³Private consulting, Mexico, Mexico, ⁴Private Physician, Mexico, Mexico, ⁵Janssen Cilag, Mexico, Mexico

PIH19	COST-EFFECTIVENESS ANALYSIS OF THE NEW FERTILITY TREATMENT (RFSH+RLH)
	Palumbo A¹, Hernandez J¹, Espallardo O², Crespo C³ ¹Centro de Asistencia a la Reproducción Humana de Canarias, Santa Cruz de Tenerife, Spain, ²Merck, Madrid, Spain, ³Oblikue Consulting, Barcelona, Spain, Spain

PIH20	WITHDRAWN

PIH21	COST-EFFECTIVENESS OF PAEDIATRIC PNEUMOCOCCAL VACCINATION IN THE NETHERLANDS; AN UPDATE FOR THE 7-VALENT AND FORECAST FOR THE 10-AND 13-VALENT PNEUMOCOCCAL CONJUGATED VACCINES (PCVS)
	Rozenbaum M¹, Sanders EA², van Hoek A¹, Jansen AG³, van de Ende A⁴, Rodenburg G², van den Dobbelsteen G⁵, Hak E⁶, Postma MJ¹ ¹Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen, Groningen, The Netherlands, ²Wilhelmina Children Hospital, University Medical Center Utrecht, Utrecht, The Netherlands, ³Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands, ⁴Academic Medical Center Amsterdam, Center for Infection and Immunity Amsterdam, Department of Medical Microbiology and the Nethe, Amsterdam, Noord-Holland, The Netherlands, ⁵The Netherlands Vaccine Institute, Bilthoven, The Netherlands, ⁶Department of Epidemiology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands

PIH22	HEALTH ECONOMIC EVALUATION OF A NEW VACCINE FOR THE PREVENTION OF HERPES ZOSTER AND POST-HERPETIC NEURALGIA IN ADULTS A GERMAN ANALYSIS
	Wasem J¹, Lang K², Papageorgiou M³, Ultsch B⁴, Martin M⁵ ¹University of Duisburg-Essen, Essen, Germany, ²CAREM GmbH, Sauerlach, Germany, ³i3 Innovus, Athens, Greece, ⁴Sanofi Pasteur MSD GmbH, Leimen, Germany, ⁵i3 Innovus, Uxbridge, Middlesex, UK

PIH23	ECONOMIC EVALUATION OF ATOSIBAN COMPARED TO BETAMIMETICS FOR THE TREATMENT OF PRETERM LABOUR IN AUSTRIA
	Wex J¹, Helmer H², Rath W³, Nielsen SK⁴ ¹PharmArchitecture Limited, Camberley, Surrey, UK, ²Medical University of Vienna, Vienna, Vienna, Austria, ³University Hospital RWTH, Aachen, Nordrhein-Westfa, Germany, ⁴Ferring International Center, Saint-Prex, Switzerland

PIH24	CHANGING THE SURGICAL WOUND CLOSURE MANAGEMENT PATHWAY: TIME AND SUPPLIES WITH PRINEO* VS. STANDARD OF CARE FOR BREAST RECONSTRUCTION SURGERY
	De Cock E¹, Van Nooten F², Raluy M¹, Müller K³, Fabré J⁴, Hargreaves J⁵ ¹United BioSource Corporation, Barcelona, Spain, ²United BioSource Corporation, London, Flanders, UK, ³ASKLEPIOS Klinik Wandsbek, Hamburg, Germany, ⁴UMC St. Radboud, Nijmegen, The Netherlands, ⁵Ethicon a Johnson & Johnson Company, Livingston, UK

PIH25	TIME AND SUPPLIES FOR WOUND MANAGEMENT DURING AND AFTER BREAST REDUCTION SURGERY IN GERMANY AND THE NETHERLANDS: PRINEO* VS STANDARD OF CARE
	De Cock E¹, Van Nooten F², Raluy M¹, Müller K³, Fabré J⁴, Hargreaves J⁵ ¹United BioSource Corporation, Barcelona, Spain, ²United BioSource Corporation, London, UK, ³ASKLEPIOS Klinik Wandsbek, Hamburg, Germany, ⁴UMC St. Radboud, Nijmegen, The Netherlands, ⁵Ethicon a Johnson & Johnson Company, Livingston, UK

INDIVIDUAL'S HEALTH Patient-Reported Outcomes Studies
PIH26	TREATMENT DURATION AND PRESCRIPTION REFILL RATE FOR VAGINAL ESTROGEN THERAPY IN MEDICAID ENROLLED WOMEN WITH ATROPHIC VAGINITIS
	Neidecker MV¹, Camacho F², Balkrishnan R³ ¹Ohio State University, Columbus, OH, USA, ²Penn State College of Medicine, Hershey, PA, USA, ³University of Michigan, Ann Arbor, MI, USA

PIH27	HEALTH RELATED QUALITY OF LIFE AND UTILITY SCORES IN MENOPAUSAL WOMEN
	Iskedjian M¹, Shapiro M², Wang M³, Farah B⁴, Walker J¹ ¹PharmIdeas Research and Consulting Inc, Oakville, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Wyeth Pharmaceuticals, Markham, ON, Canada, ⁴PharmIdeas Research and Consulting Inc, Ottawa, ON, Canada

PIH28	VALIDATION OF THE SF-36 IN PATIENTS WITH ENDOMETRIOSIS
	Stull D¹, Wasiak R¹, Kreif N¹, Colligs A², Seitz C², Gerlinger C² ¹United BioSource--Europe, London, UK, ²Bayer Schering Pharma AG, Berlin, Germany

PIH29	VALIDATION AND CROSS-NATIONAL EQUIVALENCE OF THE EYELASH SATISFACTION QUESTIONNAIRE
	Burgess SM¹, Hansen JE², Cole JC³, Dang J⁴ ¹Allergan, Inc, Irvine, CA, USA, ²Allergan, Inc., Irvine, CA, USA, ³Independent Consultant, Torrance, CA, USA, ⁴Consulting Measurement Group, Torrance, CA, USA

PIH30	SYMPTOMS AND IMPACT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD): CONCEPTS AND MEASUREMENT
	Rofail D¹, Abetz L¹, Lindemann M², Filonenko A², Colligs A², Endicott J³ ¹Mapi Values Ltd, Bollington, Cheshire, UK, ²Bayer Schering Pharma AG, Berlin, Germany, ³Columbia Univeristy College of Physicians and Surgeons, New York, NY, USA

PIH31	WITHDRAWN


PIH32	WOMEN'S PREFERENCES FOR OVARIAN STIMULATING HORMONES IN THE TREATMENT OF INFERTILITY
	Espallardo O¹, Lizan L², Polanco C¹, Paz S², Palumbo A³, de La Fuente P⁴, Rodríguez M⁵, Sánchez F⁶, Martínez-Salazar J⁷, Lizán C⁸, Marqueta J⁹ ¹Merck Serono, Madrid, Spain, ²Jaume I University, Castellon, Spain, ³Centro de Asistencia a la Reproducción Humana de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁴CEFIVA, Oviedo, Spain, ⁵IVI Castellón, Castellón, Spain, ⁶GINEMED, Sevilla, Spain, ⁷IVI Madrid, Madrid, Spain, ⁸IVI Alicante, Madrid, Spain, ⁹IBI, Palma de Mallorca, Spain

PIH33	DRUG USE BEFORE AND DURING PREGNANCY IN REPUBLIC OF SERBIA
	Petric M¹, Ilic K², Tasic L³ ¹University of Belgrade , Faculty of Pharmacy, Belgrade, Serbia, Serbia and Montenegro, ²Faculty of Pharmacy, Belgrade, Serbia and Montenegro, ³University of Belgrade, Faculty of Pharmacy, Belgrade, Serbia and Montenegro

PIH34	WITHDRAWN


PIH35	THE APPLICATIONS OF GEOGRAPHIC INFORMATION SYSTEM TO QUALITY OF LIFE STUDIES: USING TAIWAN AS AN EXAMPLE
	Yang JJ¹, Yao G² ¹National Taiwan University, Taipei, Taiwan, Taiwan, ²National Taiwan University, Taipei, Taiwan

PIH36	DETERMINANTS OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN POSTMENOPAUSAL WOMEN ENROLLED IN POSSIBLE EU ®
	Freemantle N¹, Martinez L², Cooper C³, Diez-Perez A⁴, Horne R⁵, Ortolani S⁶, Pfeilschifter J⁷, Shepherd S⁸, Marciniak A⁸, Gitlin M⁹, Guillemin F¹⁰ ¹University of Birmingham, Birmingham, UK, ²French Society of General Practitioners, Bois d'Arcy, France, ³MRC Epidemiology Resource Center, Southhampton, UK, ⁴Dept de Medicina, Barcelona, Spain, ⁵The School of Pharmacy, University of London, London, UK, ⁶Instituto Auxologico Italiano, Milan, Italy, ⁷Alfried Krupp Krankenhaus, Essen, Germany, ⁸Amgen Ltd, Uxbridge, UK, ⁹Amgen Europe GmbH, Zug, Switzerland, ¹⁰Nancy-Univiersity EA 4003, Nancy, France

PIH37	ASSESSMENT OF THE QUALITY OF LIFE IN WOMEN WITH VENOUS DISEASE
	Taieb C PFSA, Boulogne , France

PIH38	RELATIONSHIP BETWEEN HEALTH-RELATED QUALITY OF LIFE AND MULTIMORBIDITY AMONG OLDER PERSONS IN GERMANY – RESULTS OF THE PRISCUS-COHORT
	Hodek JM, Greiner W University of Bielefeld, Bielefeld, Germany

PIH39	VALIDITY AND RELIABILITY OF QUALITY OF LIFE ENJOYMENT AND SATISFACTION QUESTIONNAIRE FOR TURKISH WOMEN
	Malhan S¹, Oksuz E¹, Baytar S², Tulunay FC³ ¹Baskent University, Ankara, Turkey, ²Baskent University, ankara, Turkey, ³Ankara University Medical School, Ankara, Turkey

PIH40	WILLINGNESS TO PAY PER QUALITY-ADJUSTED LIFE YEAR OF CHRONIC PROSTATITIS PATIENTS IN CHINA
	Zhao FL¹, Wu JH², Yue M², Li SC¹ ¹University of Newcastle, Callaghan, Australia, ²306 Hospital of PLA, Beijing, China

INDIVIDUAL'S HEALTH Health Care Use & Policy Studies
PIH41	PRESCRIPTION PATTERNS AND EXPENDITURE OF LONG-TERM BENZODIAZEPINE TREATMENT IN ELDERLY OUTPATIENTS IN TAIWAN
	Cheng JS¹, Chen CY², Lin KM³, Shih YT² ¹National Health Research Institutes, Jhunan Town, Miaoli County, Taiwan, ²National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan, ³National Health Research Institutes, Taipei, Taiwan

PIH42	RESULTS OF AN OBSERVATIONAL STUDY IN 574 COMMUNITY PHARMACIES IN SPAIN CHARACTERIZING PATIENT PROFILES OF MEN ASKING FOR ERECTILE DYSFUNCTION MEDICATION
	Martí B¹, Ibañez J², Machuca M³, Pol-Yanguas E⁴, Schnetzler G⁵, Pascual Renedo V⁶ ¹Health Outcomes Research, Pfizer, Spain, ²Ibañez Pharmacy, Barcelona, Barcelona, Spain, ³Machuca Pharmacy, Seville, Seville, Spain, ⁴Pharmacy, Alicante, Alicante, Spain, ⁵Pfizer International Operations, Paris, France, ⁶Pfizer Spain, Madrid, Madrid, Spain

PIH43	EARLY ASSESSMENT OF A NEW TREATMENT FOR ADOLESCENT IDIOPATHIC SCOLIOSIS
	Boomkamp IS, Hummel JM, IJzerman MJ, Verkerke GB University of Twente, Enschede, The The Netherlands

PIH44	VARIATIONS IN CHANGES OF PRESCRIBING BEHAVIORS AMONG PHYSICIANS AFTER THE RELEASE OF WHI REPORT
	Chen WC, Tang CH, Pwu RF, Shen WC, Hung ST Taipei Medical University, Taipei, Taiwan

POSTER PRESENTATIONS SESSION I
SET-UP:	Sunday, 25 October, 11:30 – 12:00
POSTER DISPLAY HOURS:	Sunday, 25 October, 12:00 – 19:30
POSTER AUTHOR DISCUSSION HOUR:	Sunday, 25 October, 17:30 – 18:30
DISMANTLE:	Sunday, 25 October, 19:30 – 20:00

RESPIRATORY-RELATED DISORDERS Clinical Outcomes Studies


PRS1	A COMPARISON OF EFFICACY AND SAFETY OF FLUTICASONE WITH BUDESONIDE AND BECLOMETHASONE IN 1:2 DOSE RATIO IN THE TREATEMENT OF BRONCHIAL ASTHMA
	Pankiewicz O, Nadzieja-Koziol A, Kwaskowski A, Jaros P, Jagodzinska K, Lach K, Rys P, Jarczewska D, Plisko R, Wladysiuk M HTA Consulting, Krakow, Poland

PRS2	SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF VARENICLINE FOR SMOKING CESSATION COMPARED WITH PLACEBO, NICOTINE REPLACEMENT THERAPY OR SUSTAINED-RELEASE BUPROPION
	Walczak J, Nogas G, Czarny I, Baginski P, Borowiack M Arcana Institute, Cracow, Poland

PRS3	A COMPARISON OF EFFICACY OF FLUTICASONE WITH BUDESONIDE AND BECLOMETHASONE IN 1:1 DOSE RATIO IN THE TREATMENT OF BRONCHIAL ASTHMA
	Pankiewicz O, Nadzieja-Koziol A, Kwaskowski A, Jaros P, Jagodzinska K, Lach K, Jarczewska D, Rys P, Wladysiuk M, Plisko R HTA Consulting, Krakow, Poland

PRS4	INDIRECT COMPARISON OF EFFICACY AND SAFETY OF FLUTICASONE AND BUDESONIDE IN THE TREATEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
	Pankiewicz O, Jagodzinska K, Nadzieja-Koziol A, Jaros P, Lach K, Kwaskowski A, Jarczewska D, Rys P, Wladysiuk M, Plisko R HTA Consulting, Krakow, Poland

PRS5	PRIMARY CARE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS FROM GENERAL PRACTICE DATABASE
	Citarella A, Menditto E, Cammarota S, De Portu S, Riegler S, Mantovani LG University of Naples, Naples, Italy

PRS6	LESS THAN 20% OF COPD PATIENTS PERSIST WITH LONG-ACTING INHALED DRUGS FOR AT LEAST THREE YEARS
	Penning-van Beest F¹, van Herk-Sukel M², Lammers JWJ³, Gale R⁴, Herings RMC¹ ¹PHARMO Institute, Utrecht, The The Netherlands, ²PHARMO Institute, Utrecht, Utrecht, The The Netherlands, ³University Medical Center Utrecht, Utrecht, The The Netherlands, ⁴Novartis AG, Horsham, UK

PRS7	IMPACT OF COUGH AND/OR SPUTUM SYMPTOMS ON THE BURDEN OF COPD IN EUROPE AND THE USA: A CROSS-SECTIONAL, OBSERVATIONAL STUDY
	Müller TA¹, Wirén A², Small M³, Cristino J³, Pike J³ ¹Nycomed GmbH, Konstanz, Germany, ²Nycomed, Taastrup, Denmark, ³Adelphi Real World, Bollington, Cheshire, UK

RESPIRATORY-RELATED DISORDERS Cost Studies
PRS8	OPTIMA MODEL-BASED COST-UTILITY ANALYSIS OF FIXED COMBINATIONS SALMETEROL/FLUTICASONE VS. BUDESONIDE/FORMOTEROL IN TREATMENT OF ASTHMA IN RUSSIA
	Kulikov A¹, Yagudina RI¹, Tolkushin A², Demko IV³, Chuchalin AG⁴ ¹Moscow Medical Academy, Moscow, Russia, ²ZAO GlaxoSmithKline Traiding, Moscow, Russia, ³Krasnoyarsk State Medical University, Krasnoyarsk, Russia, ⁴Ministry of Health and Social Development of Russian Federation; SRI of Pulmonology, Moscow, Russia

PRS9	THE IMPACT AND COSTS OF REIMBURSED SMOKING CESSATION USING VARENICLINE IN DENMARK
	Poulsen PB, Randskov HJ, Dollerup J Pfizer Denmark ApS., Ballerup, Denmark

PRS10	THE ECONOMIC IMPLICATION OF EARLY DETECTION OF COPD IN GENERAL PRACTICE IN DENMARK
	Poulsen PB¹, Dollerup J¹, Søndergaard JD¹, Hansen G¹, Holt J², Jensen JL², Lavik B³, Løkke A⁴, Ulrik CS⁵, Dahl R⁶ ¹Pfizer Denmark ApS., Ballerup, Denmark, ²Boehringer Ingelheim, Copenhagen, Denmark, ³General Practice, Rødovre, Denmark, ⁴The Regional Hospital Silkeborg, Silkeborg, Denmark, ⁵Hvidovre Hospital, Hvidovre, Denmark, ⁶Aarhus University Hospital, Aarhus, Denmark

PRS11	ANALYSIS OF ASTHMA-RELATED OUTCOMES AND COSTS FOR PERSISTENT ASTHMA PATIENTS TREATED WITH BECLOMETHASONE DIPROPIONATE HFA OR BUDESONIDE INHALATION POWDER
	Lage MJ¹, Gross G², Brewster C³, Spalitto A³ ¹HealthMetrics Outcomes Research, LLC, Groton, CT, USA, ²Dallas Allergy and Asthma Center, Dallas, TX, USA, ³Teva Respiratory, Horsham, PA, USA

PRS12	THE CZECH BURDEN STUDY: BURDEN AND QUALITY OF LIFE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATION
	Skoupá J¹, Blahová M², Kašák V³, Cerna V¹, Malý M⁴ ¹Pharma Projects, Prague, Czech Republic, ²Thomayer University Hospital, Prague, Czech Republic, ³Lerymed s.r.o., Prague, Czech Republic, ⁴National Institute of Public Health, Prague, Czech Republic

PRS13	THE CZECH BURDEN STUDY: SUBGROUP ANALYSIS (BURDEN AND QUALITY OF LIFE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATION)
	Skoupá J¹, Kašák V², Blahová M³, Cerna V¹, Malý M⁴ ¹Pharma Projects, Prague, Czech Republic, ²Lerymed s.r.o., Prague, Czech Republic, ³Thomayer University Hospital, Prague, Czech Republic, ⁴National Institute of Public Health, Prague, Czech Republic

PRS14	MEDICAL AND PRODUCTIVITY COSTS ATTRIBUTABLE TO OBESITY IN WORKING ADULTS WITH ASTHMA IN THE U.S.
	Suh DC¹, Kim CM², Kwon JW¹, Choi IS¹, Yang JH¹, Barone JA¹ ¹Rutgers University, Piscataway, NJ, USA, ²Catholic University, Seoul, South Korea

PRS15	NEW PHARMACOECONOMIC MODEL OF ASTHMA MAINTENANCE TREATMENT (OPTIMA) IN RUSSIA. TO TREAT OR NOT TO TREAT: MAINTENANCE TREATMENT VS. NO MAINTENANCE TREATMENT
	Yagudina RI¹, Kulikov A¹, Demko IV², Tolkushin A³, Ogorodova LM⁴, Chuchalin AG⁵ ¹Moscow Medical Academy, Moscow, Russia, ²Krasnoyarsk State Medical University, Krasnoyarsk, Russia, ³GlaxoSmithKline, Moscow, Russia, ⁴Siberian State Medical University, Tomsk, Russia, ⁵Ministry of Health and Social Development of Russian Federation; SRI of Pulmonology, Moscow, Russia

PRS16	COST EFFECTIVENESS OF VARENICLINE COMPARED WITH EXISTING SMOKING CESSATION STRATEGIES IN HONG KONG
	Lee KK, Lee VWY, Chow DP The Chinese University of Hong Kong, Shatin, Hong Kong

PRS17	COST-EFFECTIVENESS OF RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS WITH PALIVIZUMAB FROM THE PERSPECTIVE OF A SOUTHERN US MEDICAID AGENCY
	Hampp C, Kauf TL, Saidi A, Winterstein AG University of Florida, Gainesville, FL, USA

PRS18	COST-EFFECTIVENESS ANALYSIS OF FORMOTEROL ASSOCIATED TO BUDESONIDE FOR MAINTENANCE AND RELIEVER THERAPY (SYMBICORT SMART) VERSUS SALMETEROL ASSOCIATED TO FLUTICASONE IN THE TREATMENT OF MODERATE TO SEVERE PERSISTENT ASTHMA UNDER THE BRAZILIAN SOCIETAL PERSPECTIVE
	Teich V¹, Niskier F¹, Pimentel A², Alameddine M² ¹MedInsight, Rio de Janeiro, Brazil, ²AstraZeneca, Cotia, SP, Brazil

PRS19	IS IT TIME FOR SMOKING CESSATION PRODUCTS TO BE REIMBURSABLE IN THAILAND?
	Thavorn K¹, Chaiyakunapruk N² ¹University of Toronto, Toronto, Ontario, Canada, ²Center of Pharmaceutical Outcomes Research, Mueng, Phitsanulok, Thailand

PRS20	ECONOMIC EVALUATION OF THE IMPACT OF THE MEXICO CITY'S NON-SMOKERS HEALTH PROTECTION ACT
	Guerrero-López CM¹, Jiménez Ruiz JA¹, Reynales-Shigematsu LM², Waters H³ ¹Instituto Nacional de Salud Pública (México), Cuernavaca, Morelos, Mexico, ²Instituto Nacional de Salud Publica, Cuernavaca, Morelos, Mexico, ³Johns Hopkins School of Public Health, Baltimore, MD, USA

PRS21	COST-EFFECTIVENESS ANALYSIS OF XOLAIR UNDER REAL LIFE CONDITIONS IN BELGIAN PATIENTS WITH SEVERE ALLERGIC ASTHMA
	Lecomte P¹, Lee CS², Van Nooten FE³, Thompson CL⁴ ¹Novartis Pharmaceuticals, Vilvoorde, Belgium, ²Matrix45, LLC, Earlysville, VA, USA, ³United BioSource Corporation, Brussels, Belgium, ⁴United BioSource Corporation, Bethesda, MD, USA

PRS22	COST-EFFECTIVENESS ANALYSIS OF TIOTROPIUM IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS IN SPAIN.
	Brosa M¹, Díaz S², Miravitlles M³, Gonzalez-Rojas N⁴, Nieves D¹ ¹Oblikue Consulting, Barcelona, Spain, ²Pfizer Spain, Madrid, Spain, ³Hospital Clínic, Barcelona, Spain, ⁴Boehringer Ingelheim, Sant Cugat del Vallés, Spain

PRS23	FRENCH GATEKEEPING COST-EFFECTIVENESS IMPACT ON CHRONIC PATIENTS TREATED WITH INHALED CORTICOSTEROIDS, IN REAL LIFE
	Maunoury F¹, VanHille JL², Véron N², Bounekkar A¹, Fantino B³, Auray JP¹, Launois R⁴ ¹Claude Bernard University Lyon 1, Villeurbanne, France, ²Regional Health Insurance Medical Service, Orléans, France, ³ADIM-AGORAS, Lyon, France, ⁴REES, Paris, France

PRS24	THE COST-EFFECTIVENESS ANALYSIS OF VARENICLINE FOR SMOKING CESSATION IN POLAND
	Walczak J, Nogas G, Dybek-Karpiuk A, Augustynska J, Stelmachowski J, Garbacka M, Obrzut G, Pawlik D Arcana Institute, Cracow, Poland

PRS25	CAN THE FRENCH GATEKEEPING SYSTEM BE COST-EFFECTIVE FOR PATIENTS WITH CHRONIC RESPIRATORY DISORDER?
	Maunoury F¹, VanHille JL², Véron N², Bounekkar A¹, Fantino B³, Auray JP¹, Launois R⁴ ¹Claude Bernard University Lyon 1, Villeurbanne, France, ²Regional Health Insurance Medical Service, Orléans, France, ³ADIM-AGORAS, Lyon, France, ⁴REES France, Paris, France

PRS26	COST-EFFECTIVENESS OF GRAZAX IN THE PAEDIATRIC POPULATION FOR THE TREATMENT OF GRASS POLLEN INDUCED RHINOCONJUNCTIVITIS IN GERMANY
	Whitehead SJ¹, Taylor MJ¹, Bech PG², Prenzler A³ ¹University of York, York, UK, ²ALK-Abelló, Hørsholm, Denmark, ³Leibniz University of Hannover, Hannover, Germany

PRS27	MARKOV MODEL FOR HEALTH-ECONOMIC EVALUATIONS OF COPD IN GERMANY
	Menn P, Holle R Institute of Health Economics & Health Care Management, Helmholtz Center Munich, Neuherberg, Germany

PRS28	ADD-ON OMALIZUMAB IN PERSISTENT DIFFICULT-TO-TREAT ASTHMA: A 12-MONTH STUDY ON CLINICAL, ECONOMIC OUTCOMES AND RELATED COST/UTILITY
	Dal Negro RW¹, Pradelli L², Micheletto C¹, Tognella S¹, Iannazzo S² ¹Ospedale Orlandi, Bussolengo, Verona, Italy, ²AdRes HE&OR, Torino, Italy

PRS29	QUALITY OF LIFE AND WORK PRODUCTIVITY IN ALLERGIC RHINITIS PATIENTS SUFFERING FROM BOTH NASAL AND OCULAR SYMPTOMS - AN OBSERVATIONAL, CROSS SECTIONAL STUDY IN 4 COUNTRIES IN EUROPE
	Gueron B¹, Virchow JC², Cristino J³ ¹GSK, Marly le Roi, France, ²Universitatsklinik Rostock, Rostock, Germany, ³Adelphi Group, Bollington, Cheshire, UK

PRS30	IMPACT OF OCULAR SYMPTOMS ON RESOURCE UTILISATION AND WORK PRODUCTIVITY IN MANAGEMENT OF AR – AN OBSERVATIONAL, CROSS SECTIONAL STUDY IN 4 COUNTRIES IN EUROPE
	Gueron B¹, Virchow JC², Cristino J³ ¹GSK, Marly le Roi, France, ²Universitatsklinik Rostock, Rostock, Germany, ³Adelphi Group, Bollington, Cheshire, UK

RESPIRATORY-RELATED DISORDERSPatient-Reported Outcomes Studies
PRS31	PRESCRIPTION PATTERNS OF AND TREATMENT ADHERENCE TO INHALED CORTICOSTEROIDS AND LEUKOTRIENE-RECEPTOR ANTAGONISTS AMONG ASTHMATIC CHILDREN
	Blais L¹, Ducharme F², Kettani FZ¹ ¹Université de Montréal, Montreal, QC, Canada, ²Univerité de Montréal, Montréal, QC, Canada

PRS32	ADJUSTING THE NICOTINE DOSE: THE KEY TO A SUCCESSFUL, “TAILORED” METHOD OF QUITTING SMOKING
	Taieb C PFSA, Boulogne , France

PRS33	DEVELOPMENT OF A PREFERENCE-BASED ALGORITHM TO REPORT UTILITIES FOR EXACERBATIONS OF COPD FROM THE EXACT
	Petrillo J¹, Macker S², Davies E³, Cairns JA¹ ¹London School of Hygiene and Tropical Medicine, London, UK, ²United BioSource Corporation, Bethesda, MD, USA, ³United BioSource Corporation, London, UK

PRS34	ITEM SELECTION AND SCORING DEFINITION OF A DISEASE-SPECIFIC INSTRUMENT TO ASSESS THE HANDICAP IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS, FOR USE IN CLINICAL ROUTINE PRACTICE
	Regnault A¹, Mueser Ruphin M², Dias-Barbosa C¹, Aguilaniu B³, Bonnefoy M⁴, Gonzalez-Bermejo J⁵, Granet G⁶, Similowski T⁵, Arnould B¹ ¹Mapi Values, Lyon, France, ²Boehringer Ingelheim France, Reims, France, ³Clinique du Mail, Grenoble, France, ⁴Centre Hospitalier Lyon Sud, Pierre Bénite, France, ⁵Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ⁶Medical practice, Sainte Foy les Lyon, France

PRS35	OPINION OF ASTHMA PATIENTS TREATED ACCORDING TO GINA 2006 GUIDELINES – THE EPAGGELIA STUDY
	Zachariadis M¹, Kostagiolas L², Yourgioti G², Panitti E², Nikas N² ¹Euroclinic, Athens, Greece, ²AstraZeneca SA, Athens, Greece

PRS36	XOLAIR QUALITY OF LIFE RESULTS AS MEASURED IN A BELGIAN OBSERVATIONAL STUDY IN PATIENTS WITH SEVERE ALLERGIC ASTHMA
	Lecomte P¹, Lee CS², Van Nooten FE³, Rentz AM⁴ ¹Novartis Pharmaceuticals, Vilvoorde, Belgium, ²Matrix45, LLC, Earlysville, VA, USA, ³United BioSource Corporation, Brussels, Belgium, ⁴United BioSource Corporation, Bethesda, DC, USA

PRS37	IMPROVEMENTS IN QUALITY OF LIFE FOR PATIENTS UNDERGOING COPD REHABILITATION AT MUNICIPALITY HEALTH CARE CENTRES IN DENMARK
	Dollerup J¹, Poulsen PB¹, Godtfredsen NS², Grann O³, Pors B⁴, Andersen KK⁵, Larsen HB⁶, Dalsgaard LS⁶, Søndergaard JD¹, Lavesen M⁷, Sørensen TB⁸ ¹Pfizer Denmark ApS., Ballerup, Denmark, ²Bispebjerg Hospital, Copenhagen, Denmark, ³The Municipality of Aalborg, Aalborg, Denmark, ⁴The Municipality of Horsens, Horsens, Denmark, ⁵Technical University of Denmark, Lyngby, Denmark, ⁶Boehringer Ingelheim, Copenhagen, Denmark, ⁷Hillerød Hospital, Hillerød, Denmark, ⁸The Regional Hospital Horsens, Brædstrup and Odder, Horsens, Denmark

PRS38	ASSOCIATION BETWEEN SMOKING AND HEALTH-RELATED QUALITY OF LIFE
	Rasch A, Greiner W University of Bielefeld, Bielefeld, Germany

PRS39	VALIDATION OF THE SPANISH VERSION OF THE “COPD AND ASTHMA SLEEP IMPACT SCALE (CASIS)” QUESTIONNAIRE
	Lahoz R¹, Galera J¹, Lleonart M¹, Miravitlles M² ¹Novartis Pharmaceuticals, Barcelona, Spain, ²Hospital Clínic, Barcelona, Spain

PRS40	IMPACT OF COUGH AND/OR SPUTUM SYMPTOMS ON HEALTH-RELATED QUALITY OF LIFE IN COPD PATIENTS: AN OBSERVATIONAL, CROSS-SECTIONAL STUDY IN EUROPE AND THE USA
	Müller TA¹, Wirén A², Small M³, Cristino J³, Pike J³ ¹Nycomed GmbH, Konstanz, Germany, ²Nycomed, Taastrup, Denmark, ³Adelphi Real World, Bollington, Cheshire, UK

PRS41	VALIDATION OF THE SPANISH VERSION OF THE “LIVING WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (LCOPD)” QUESTIONNAIRE
	Lahoz R¹, Galera J¹, Lleonart M¹, Miravitlles M² ¹Novartis Pharmaceuticals, Barcelona, Spain, ²Hospital Clínic, Barcelona, Spain

PRS42	VALIDATION OF THE SPANISH VERSION OF THE “COPD AND ASTHMA FATIGUE SCALE (CAFS)” QUESTIONNAIRE
	Galera J¹, Lahoz R¹, Lleonart M¹, Miravitlles M² ¹Novartis Pharmaceuticals, Barcelona, Spain, ²Hospital Clínic, Barcelona, Spain

PRS43	RELIABILITY AND VALIDITY OF THE SMOKER COMPLAINT SCALE
	Eminsoy G, Malhan S, Ersoy K, Erdal R Baskent University, Ankara, Turkey

PRS44	CLINICO-PHARMACOLOGICAL PRESENTATION AND THE OUTCOME OF QUALITY OF LIFE OF PATIENTS WITH EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
	Bawoh M Yaroslavl State Medical Academy, Yaroslavl, Russia

RESPIRATORY-RELATED DISORDERSHealth Care Use & Policy Studies
PRS45	CLINICAL AND ECONOMIC OUTCOME OF MECHANICALLY VENTILATED PATIENTS UNDER DRG 475: A POPULATION-BASED STUDY
	Bouza C, Lopez T, Sastre M Carlos III Health Institute, Madrid, Spain

PRS46	OFF-LABEL PRESCRIBING OF INHALED CORTICOSTEROID/ LONG ACTING BETA-AGONIST COMBINATION PRODUCTS IN COPD PATIENTS
	Rigney U, Emmas C, Morais J AstraZeneca UK Ltd, Luton, UK

PRS47	SEASONAL VERSUS NEEDS-BASED IMMUNIZATION SCHEDULES – THE EXAMPLE OF RSV
	Hampp C, Winterstein AG University of Florida, Gainesville, FL, USA

PRS48	A SURVEY OF TOBACCO CESSATION INTERVENTIONS IN THE DENTAL SETTING IN JAPAN: NICOTINE REPLACEMENT THERAPY, ATTITUDES TOWARDS TOBACCO CESSATION EDUCATION, AND BARRIERS TO CESSATION COUNSELING
	Nakao H¹, Yoshimi I¹, Fukuda Y², Sata F¹, Imai H¹ ¹National Institute of Public Health, Wako-shi, Saitama, Japan, ²Yamaguchi University, Ube, Yamaguchi, Japan

PRS49	FACTORS RELATED TO STOP SMOKING'S ATTEMPTS AMONG A FRENCH COHORT OF SMOKERS: (FOCUS STUDY)
	Benhaddi H¹, Aubin HJ², Thomas D³, Stoebner-Delbarre A⁴, Peiffer G⁵, Vicaut E⁶, Solesse A¹ ¹Pfizer, Paris, France, ²Paul Brousse Hospital, Villejuif, France, ³Cardiology Institut, Paris, France, ⁴Epidaure - CRLC Val d'Aurelle, Montpellier , France, ⁵CHR MED D, Metz, France, ⁶Lariboisière St Louis, Hôpital F. Widal, Paris, France

POSTER PRESENTATIONS SESSION I
SET-UP:	Sunday, 25 October, 11:30 – 12:00
POSTER DISPLAY HOURS:	Sunday, 25 October, 12:00 – 19:30
POSTER AUTHOR DISCUSSION HOUR:	Sunday, 25 October, 17:30 – 18:30
DISMANTLE:	Sunday, 25 October, 19:30 – 20:00

URINARY/KIDNEY DISORDERSClinical Outcome Studies
PUK1	USE OF A BAYESIAN MIXED TREATMENT META ANALYSIS TO SUPPORT REIMBURSEMENT DECISION MAKING OF PHOSPHATE BINDER THERAPY IN END-STAGE RENAL DISEASE
	Stevens J¹, Keith MS², Hodgkins P² ¹The University of Sheffield, Sheffield, UK, ²Shire Pharmaceuticals, Wayne, PA, USA

PUK2	EFFECTIVENESS AND COST-EFFICACY OF PHOSPHATBINDERS IN HEMODIALYSIS
	Brunner-Ziegler S, Fröschl B, Zsifkovits J Gesundheit Österreich GmbH, Vienna, Austria

PUK3	FORECASTING SPANISH RENAL REPLACEMENT THERAPY TRENDS FROM REGISTRY DATA: A QUANTILE REGRESSION APPROACH
	Villa G, Cuervo J, Ortiz LF, Rebollo P BAP Health Outcomes Research, Oviedo, Asturias, Spain
	¹Université de Montréal, Montreal, QC, Canada, ²Hôpital du Sacré-Coeur de Montréal, Montreal, QC, Canada

URINARY/KIDNEY DISORDERSCost Studies
PUK4	THE IMPACT ON COSTS OF TREATING COMPLICATIONS DUE TO CRONIC KIDNEY DISEASE IN PATIENTS UNDERGOING HEMODIALYSIS IN THE PUBLIC HEALTH CARE SYSTEM IN BRAZIL
	Saggia MG Roche Brazil, Sao Paulo, SP, Brazil

PUK5	THE IMPACT ON COSTS OF TREATING COMPLICATIONS DUE TO CRONIC KIDNEY DISEASE IN PATIENTS UNDERGOING HEMODIALYSIS IN THE PRIVATE HEALTH CARE SYSTEM IN BRAZIL
	Saggia MG Roche Brazil, Sao Paulo, SP, Brazil

PUK6	WITHDRAWN


PUK7	ANALYSIS OF THE PHARMACOTHERAPY COST OF PATIENTS WITH KIDNEY TRANSPLANTATION IN BULGARIA
	Georgieva SS¹, Paskalev ED², Petrova GI³ ¹University Hospital “Alexandrovska”, Sofia, Bulgaria, ²Medical University in Sofia, University Hospital “Alexandrovska”, Sofia, Bulgaria, ³Medical University, Faculty of Pharmacy, Sofia, Bulgaria

PUK8	THE COST-EFFECTIVENESS OF PHOSPHATE BINDERS FOR THE TREATMENT OF HYPERPHOSPHATEMIA IN CHRONIC KIDNEY DISEASE (CKD)
	Keith MS¹, Carlton R², Meissner BL² ¹Shire Pharmaceuticals, Wayne, PA, USA, ²Xcenda, Palm Harbor, FL, USA

PUK9	OPEN COLPOSUSPENSION, TENSION-FREE VAGINAL TAPE AND TENSION-FREE OBTURATOR TAPES IN THE MANAGEMENT OF STRESS URINARY INCONTINENCE IN WOMEN: A COLOMBIAN COST-EFFECTIVENESS MODEL
	Gamboa OA, Chicaiza L, Castillo JS, Garcia M, Sanchez J, Delgado ME, Rubio JA, Lomanto A National University of Colombia, Bogota, Colombia

PUK10	COST-EFFECTIVENESS OF COMBINATION THERAPY FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
	Baker TM¹, Black L², Bjerklund Johansen TE³ ¹United BioSource Inc., Bethesda, MD, USA, ²GlaxoSmithKline, Research Triangle Park, NC, USA, ³Aarhus University Hospital, Arhus, Denmark

PUK11	COST-MINIMIZATION ANALYSIS: MIRCERA (METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA) VS. ARANESP (DARBEPOETIN ALFA) IN PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) WHO ARE NOT RECEIVING HAEMODIALYSIS, IN POLISH SETTING
	Kawalec P¹, Kuzma J¹, Szkultecka-Debek M², Russel-Szymczyk M², Slizien-Debska A³, Malyszko J⁴, Durlik M⁵ ¹Centrum HTA, Krakow, Poland, ²Roche Polska, Warsaw, Poland, ³Medical University of Gdansk, Gdansk, Poland, ⁴Medical University of Bialystok, Bialystok, Poland, ⁵Warsaw Medical University, Warsaw, Poland

PUK12	COST-EFFECTIVENESS OF ACE INHIBITOR THERAPY TO PREVENT DIALYSIS IN NON-DIABETIC NEPHROPATHY – INFLUENCE OF THE ACE INSERTION / DELETION POLYMORPHISM
	Vegter S¹, Perna A², Hiddema W¹, Ruggenenti P², Remuzzi G², Navis G³, Postma MJ¹ ¹University of Groningen, Groningen, The The Netherlands, ²Mario Negri Institute for Pharmacological Research, Ranica, Italy, ³University Medical Centre Groningen (UMCG), Groningen, The The Netherlands
	¹AstraZeneca, Espoo, Finland, ²ESiOR Oy, Kuopio, Finland, ³Seinäjoki Central Hospital, Seinäjoki, AL, Finland

URINARY/KIDNEY DISORDERSPatient-Reported Outcomes Studies
PUK13	DEVELOPMENT AND VALIDATION OF A QUESTIONNAIRE (SIGIT-QOL) TO EVALUATE THE EFFECTS OF GASTROINTESTINAL SYMPTOMS ON HEALTH RELATED-QUALITY OF LIFE IN SOLID-ORGAN TRANSPLANT RECIPIENTS WITH A FUNCTIONING GRAFT
	Font B¹, Mora S¹, Lahoz R¹, Ortega F², Mypaciente Study Group .¹ ¹Novartis Farmaceutica SA, Barcelona, Spain, ²Hospital Universitario Central de Asturias, Oviedo, Spain

PUK14	HOW DO PATIENTS DESCRIBE THEIR SYMPTOMS OF INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME (IC/PBS)? QUALITATIVE INTERVIEWS WITH PATIENTS TO SUPPORT THE DEVELOPMENT OF A PATIENT-REPORTED SYMPTOM-BASED SCREENER FOR IC/PBS
	Abraham L¹, Arbuckle R², Bonner N², Crook T¹, Humphrey L², Mills IW¹, Moldwin RM³, Nordling J⁴, Scholfield D¹, Symonds T¹, van de Merwe JP⁵ ¹Pfizer Ltd, Sandwich, Kent, UK, ²Mapi Values Ltd, Bollington, UK, ³Long Island Jewish Medical Center, New York, NY, USA, ⁴University of Copenhagen, Herlev, Herlev, Denmark, ⁵Erasmus Medical Centre, Rotterdam, CA, The The Netherlands

PUK15	STRESS URINARY INCONTINENCE: ASSESSMENT OF WOMEN'S PREFERENCES
	Riou França L¹, Zylberman M², Launois R¹ ¹REES France, Paris, France, ²Lilly France, SURESNES, Ile de France, France

PUK16	QUALITY OF LIFE OF ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) IN RENAL TRANSPLANT RECIPIENTS WITH GASTROINTESTINAL TRACT COMPLAINTS TO MYCOPHENOLATE MOFETIL (MMF). MYVIDA STUDY
	Andrés I¹, Font B¹, Mora S¹, Lahoz R¹, Ortega F² ¹Novartis Farmaceutica SA, Barcelona, Spain, ²Hospital Universitario Central de Asturias, Oviedo, Spain
RESPIRATORY-RELATED DISORDERSHealth Care Use & Policy Studies
PUK17	CHRONIC OPIOID THERAPY IN ELDERLY PATIENTS WITH IMPAIRED RENAL FUNCTION OR WITH A HIGH RISK OF KIDNEY FAILURE IN GERMANY
	Biteeva I¹, Kruse S² ¹Janssen-Cilag, Neuss, NRW, Germany, ²Janssen-Cilag GmbH, Neuss, NRW, Germany